Provectus Biopharmaceuticals (PVCT) 10-K12 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Mar. 02, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	PVCT
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	315545
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		185,171,159
Entity Public Float			$142,203,263

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets
Cash and cash equivalents	$17,391,601	$15,696,243
Short-term receivable - settlement	733,333
Other current assets	978,000
Total Current Assets	19,102,934	15,696,243
Equipment and furnishings, less accumulated depreciation of $437,863 and $429,331, respectively	92,171	30,113
Patents, net of amortization of $8,131,737 and $7,460,617, respectively	3,583,708	4,254,828
Long-term receivable - settlement, net of discount	3,378,345
Other assets	27,000	27,000
Total Assets	26,184,158	20,008,184
Current Liabilities
Accounts payable - trade	440,702	348,869
Accrued consulting expense	91,282	61,282
Other accrued expenses	315,738	102,795
Total Current Liabilities	847,722	512,946
Long-Term Liability
Warrant liability	146,560	12,866,572
Total Liabilities	994,282	13,379,518
Stockholders' Equity
Preferred stock; par value $.001 per share; 25,000,000 shares authorized; Series A 8% convertible preferred stock, 0 and 33,334 shares issued and outstanding, respectively, liquidation preference $0.75 (for 2013 in aggregate $25,001)		33
Common stock; par value $.001 per share; 300,000,000 shares authorized; 184,796,275 and 159,751,724 shares issued and outstanding, respectively	184,796	159,752
Paid-in capital	181,298,890	152,519,701
Accumulated deficit	-156,293,810	-146,050,820
Total Stockholders' Equity	25,189,876	6,628,666
Total Liabilities and Stockholders' Equity	$26,184,158	$20,008,184

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accumulated depreciation on equipment and furnishings	$437,863	$429,331
Amortization on patents	8,131,737	7,460,617
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	25,000,000	25,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	184,796,275	159,751,724
Common stock, shares outstanding	184,796,275	159,751,724
Series A 8% Convertible Preferred Stock [Member]
Preferred stock, shares issued	0	33,334
Preferred stock, shares outstanding	0	33,334
Preferred stock, liquidation preference per share	$0.75	$0.75
Aggregate liquidation preference		$25,001
Convertible preferred stock	8.00%	8.00%

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
Consolidated Statements of Operations (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Gain on settlement - net of discount	$4,178,345
Operating expenses
Research and development	5,137,927	3,595,555	5,005,459
General and administrative	11,002,326	8,761,264	8,661,040
Amortization	671,120	671,120	671,120
Total operating loss	-12,633,028	-13,027,939	-14,337,619
Investment income	5,645	1,325	1,347
Gain (loss) on change in fair value of warrant liability	2,384,393	-14,671,130	1,767,918
Net income (loss)	-10,242,990	-27,697,744	-12,568,354
Dividends on preferred stock	0	-1,188,648	-183,187
Net loss applicable to common shareholders	($10,242,990)	($28,886,392)	($12,751,541)
Basic and diluted loss per common share	($0.06)	($0.22)	($0.11)
Weighted average number of common shares outstanding - basic and diluted	175,828,004	132,000,796	112,986,636

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Paid in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2011	$10,019,740	$3,531	$110,597	$115,690,334	($105,784,722)
Beginning Balance, shares at Dec. 31, 2011		3,531,665	110,596,798
Issuance of stock for services	456,500		550	455,950
Issuance of stock for services, shares			550,000
Issuance of warrants for services	1,512,026			1,512,026
Issuance of common stock and warrants pursuant to Regulation D	4,790,544		6,228	4,784,316
Issuance of common stock and warrants pursuant to Regulation D, shares			6,227,647
Preferred stock conversions into common stock		-1,053	1,053
Preferred stock conversions into common stock, shares		-1,053,480	1,053,480
Employee compensation from stock options	183,028			183,028
Net loss	-12,568,354				-12,568,354
Ending Balance at Dec. 31, 2012	4,393,484	2,478	118,428	122,625,654	-118,353,076
Ending Balance, shares at Dec. 31, 2012		2,478,185	118,427,925
Issuance of stock for services	526,000		750	525,250
Issuance of stock for services, shares			750,000
Issuance of warrants for services	1,786,824			1,786,824
Reclassification of warrant liability	4,402,078			4,402,078
Cash proceeds from exercise of warrants and stock options	3,433,392		6,320	3,427,072
Cash proceeds from exercise of warrants and stock options, Shares			6,319,594
Issuance of common stock and warrants pursuant to Regulation D	18,419,335		28,409	18,390,926
Issuance of common stock and warrants pursuant to Regulation D, shares			28,409,353
Issuance of preferred stock and warrants pursuant to Regulation D	1,252,050	3,400		1,248,650
Issuance of preferred stock and warrants pursuant to Regulation D, shares		3,400,001
Preferred stock conversions into common stock		-5,845	5,845
Preferred stock conversions into common stock, shares		-5,844,852	5,844,852
Dividends on preferred stock	-29,063			-29,063
Employee compensation from stock options	142,310			142,310
Net loss	-27,697,744				-27,697,744
Ending Balance at Dec. 31, 2013	6,628,666	33	159,752	152,519,701	-146,050,820
Ending Balance, shares at Dec. 31, 2013		33,334	159,751,724
Issuance of stock for services	418,250		300	417,950
Issuance of stock for services, shares			300,000
Issuance of warrants for services	2,321,327			2,321,327
Reclassification of warrant liability	10,335,619			10,335,619
Cash proceeds from exercise of warrants and stock options	4,490,757		14,926	4,475,831
Cash proceeds from exercise of warrants and stock options, Shares			14,926,617
Issuance of common stock and warrants pursuant to Regulation D	11,122,602		9,785	11,112,817
Issuance of common stock and warrants pursuant to Regulation D, shares			9,784,600
Preferred stock conversions into common stock		-33	33
Preferred stock conversions into common stock, shares		-33,334	33,334
Employee compensation from stock options	115,645			115,645
Net loss	-10,242,990				-10,242,990
Ending Balance at Dec. 31, 2014	$25,189,876		$184,796	$181,298,890	($156,293,810)
Ending Balance, shares at Dec. 31, 2014			184,796,275

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
Consolidated Statements of Cash Flows (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash Flows From Operating Activities
Net loss	($10,242,990)	($27,697,744)	($12,568,354)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	8,532	6,366	6,167
Amortization of patents	671,120	671,120	671,120
Compensation through issuance of stock options	115,645	142,310	183,028
Issuance of stock for services	418,250	526,000	456,500
Issuance of warrants for services	2,321,327	1,786,824	1,512,026
(Gain) loss on change in fair value of warrant liability	-2,384,393	14,671,130	-1,767,918
Gain on settlement	-4,178,345
Settlement receivable	66,667
Other current assets	-978,000
Increase (decrease) in liabilities
Accounts payable	91,833	105,434	142,333
Accrued expenses	242,943	-103,912	106,367
Net cash used in operating activities	-13,847,411	-9,892,472	-11,258,731
Cash Flows From Investing Activities
Capital expenditures	-70,590	-6,650	-15,885
Net cash used in investing activities	-70,590	-6,650	-15,885
Cash Flows From Financing Activities
Net proceeds from sales of preferred stock and warrants		2,550,000
Net proceeds from sales of common stock and warrants	11,122,602	18,419,335	4,790,544
Proceeds from exercises of warrants and stock options	4,490,757	3,433,392
Cash paid for preferred dividends		-29,063
Net cash provided by financing activities	15,613,359	24,373,664	4,790,544
Net change in cash and cash equivalents	1,695,358	14,474,542	-6,484,072
Cash and cash equivalents, at beginning of period	15,696,243	1,221,701	7,705,773
Cash and cash equivalents, at end of period	17,391,601	15,696,243	1,221,701
Supplemental Disclosure of Noncash Investing and Financing Activities
Reclassification of warrant liability to equity due to exercise of warrants	$10,335,619	$4,402,078

Organization_and_Significant_A

Organization and Significant Accounting Policies	12 Months Ended
Organization and Significant Accounting Policies	Dec. 31, 2014
Accounting Policies [Abstract]
Organization and Significant Accounting Policies	1. Organization and Significant Accounting Policies
	Nature of Operations
	Provectus Biopharmaceuticals, Inc. (together with its subsidiaries, the “Company”) is a biopharmaceutical company that is focusing on developing minimally invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer including melanoma, breast cancer, and cancers of the liver. To date, the Company has no revenues from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates, or sell or license the Company’s OTC products or non-core technologies.
	Principles of Consolidation
	Intercompany balances and transactions have been eliminated in consolidation.
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
	Cash Concentrations
	Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits of $250,000 although the Company seeks to minimize this through treasury management. We have never experienced any losses related to these balances.
	Equipment and Furnishings
	Equipment and furnishings are stated at cost. Depreciation of equipment is provided for using the straight-line method over the estimated useful lives of the assets. Computers and laboratory equipment are being depreciated over five years; furniture and fixtures are being depreciated over seven years.
	Long-Lived Assets
	The Company reviews the carrying values of its long-lived assets for possible impairment whenever an event or change in circumstances indicates that the carrying amount of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less cost to sell. Management has determined there to be no impairment.
	Patent Costs
	Internal patent costs are expensed in the period incurred. Patents purchased are capitalized and amortized over the remaining life of the patent.
	Patents at December 31, 2014 were acquired as a result of the merger with Valley Pharmaceuticals, Inc. (“Valley”) on November 19, 2002. The majority stockholders of Provectus also owned all of the shares of Valley and therefore the assets acquired from Valley were recorded at their carry-over basis. The patents are being amortized over the remaining lives of the patents, which range from 2-7 years at December 31, 2014. Annual amortization of the patents is expected to approximate $671,000 for each of the next two years, $659,000 in 2017 and 2018, and $547,000 in 2019.

	Research and Development
	Research and development costs are charged to expense when incurred. An allocation of payroll expenses to research and development is made based on a percentage estimate of time spent. The research and development costs include the following: payroll, consulting and contract labor, lab supplies and pharmaceutical preparations, legal, insurance, rent and utilities, and depreciation.
	Income Taxes
	The Company accounts for income taxes under the liability method in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 “Income Taxes”. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established if it is more likely than not that all, or some portion, of deferred income tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset would increase income in the period such determination was made.
	The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained upon an examination. Any recognized income tax positions would be measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement would be reflected in the period in which the change in judgment occurs. The Company would recognize any corresponding interest and penalties associated with its income tax positions in income tax expense. There were no income taxes, interest or penalties incurred in 2014, 2013 or 2012. Tax years going back to 2011 remain open for examination by the IRS.
	Basic and Diluted Loss Per Common Share
	Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options and warrants and convertible preferred stock as they are antidilutive. Potential common shares excluded from the calculation for the years ended December 31, 2014, 2013 and 2012, respectively, are 63,235,956, 73,037,416 and 30,038,017 from warrants, 10,845,098, 15,322,206 and 15,140,956 from options, and 0, 33,334 and 2,478,185 from convertible preferred shares.
	Derivative Instruments
	The warrants issued in conjunction with convertible preferred stock in March and April 2010 private placements include a reset provision if the Company issues additional warrants, in certain circumstances as defined in the agreement, below the exercise price of $1.00. Effective January 1, 2009, the reset provision of these warrants preclude equity accounting treatment under ASC 815. Accordingly, the Company is required to record the warrants as liabilities at their fair value upon issuance and remeasure the fair value at each period end with the change in fair value recorded in the statement of operations. When the warrants are exercised or cancelled, they are reclassified to equity. The Company uses the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used at December 31, 2014 include a weighted average term of 0.2 years, a 5% probability that the warrant exercise price would be reset, a volatility of 63.7% and a risk free interest rate that ranges between 0.03% and 0.04%. Significant assumptions used at December 31, 2013 include a weighted average term of 1.2 years, a 5% probability that the warrant exercise price would be reset, a volatility range between 64.7% and 69.5% and a risk free interest rate range between 0.13% and 0.38%.
	Additionally, the Series A and Series C Warrants issued in conjunction with the January 2011 registered direct public offering include a reset provision if the Company issues additional warrants, in certain circumstances as defined in the agreement, below the exercise price of $1.12. During 2012, the warrant exercise price was reset to $0.675. Significant assumptions used at December 31, 2014 include a weighted average term of 1.0 years, a 5% probability that the warrant exercise price would be further reset, a volatility of 159.2% and a risk free interest rate range of 0.25%. Significant assumptions used at December 31, 2013 include a weighted average term of 2.0 years, a 5% probability that the warrant exercise price would be further reset, a volatility of 64.7% and a risk free interest rate that ranges between 0.38% and 0.78%.
	On February 22, 2013, the Company entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of an aggregate of $2,550,000 of Units at a purchase price of $0.75 per Unit. Each Unit consists of one share of Series A 8% Convertible Preferred Stock, par value $.001 per share, and a warrant to purchase one and one-quarter shares of the Company’s common stock, par value $.001 per share (subject to adjustment) at an exercise price of $1.00 per whole share (subject to adjustment). The total Series A 8% Convertible Preferred Stock issued was 3,400,001 shares, and the total warrants were 4,250,000. The Company used the net proceeds of the private placement for working capital, FDA trials, securing licensing partnerships, and general corporate purposes.

	The Company determined that warrants issued in February 2013 with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. At June 30, 2014, there are no remaining 2013 warrants and therefore no associated warrant liability. Significant assumptions used at December 31, 2013 include a weighted average term of 4.1 years, a 5% probability that the warrant exercise price would be reset, volatility of 67.2% and a risk free interest rate range between 0.78% and 1.78%.
	Reclassification of Prior Period Balances
	Certain reclassifications have been made to prior period amounts to conform to current-year presentation.
	Fair Value of Financial Instruments
	The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, short-term settlement receivable, other current assets and accounts payable approximate their fair value because of the short-term nature of these items. Cash equivalents are measured on a recurring basis within the fair value hierarchy using Level 1 inputs.
	The fair value of derivative instruments is determined by management with the assistance of an independent third party valuation specialist. Certain derivatives with limited market activity are valued using externally developed models that consider unobservable market parameters.
	Stock-Based Compensation
	The compensation cost relating to share-based payment transactions is measured based on the fair value of the equity or liability instruments at date of issuance and is expensed on a straight-line basis. The Company utilizes the Black-Scholes option-pricing model for purposes of estimating the fair value of each stock option on the date of grant. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock (as determined by reviewing its historical public market closing prices).
	Warrants to non-employees are generally vested and nonforfeitable upon the date of the grant. Accordingly fair value is determined on the grant date.
	Recent Accounting Pronouncements
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.
	The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2017. The Company currently does not have revenues but will consider any related impact going forward.
	In June 2014, the FASB issued Accounting Standards Update 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (ASU 2014-10), which eliminates the concept of a development stage entity (DSE) from U.S. GAAP. This change rescinds certain financial reporting requirements that have historically applied to DSEs and is intended to result in cost-savings for affected entities, such as certain start-up or research and development entities. The new standard also changes one related aspect of the variable interest entity (VIE) consolidation guidance in Topic 810.

	ASU 2014-10 is effective for public entities for annual reporting periods beginning after December 15, 2014 and interim periods therein. Early adoption is permitted. We early adopted ASU 2014-10 in our consolidated financial statements as of the third quarter of fiscal 2014.
	In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (ASU 2014-15), which addresses when and how to disclose going-concern uncertainties in the financial statements. ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year after the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The amended guidance is not expected to have a material impact on the Company’s consolidated financial statements.

Commitments

Commitments	12 Months Ended
Commitments	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments	2. Commitments

	Leases

	The Company leases office and laboratory space in Knoxville, Tennessee on an annual basis, renewable for one year at our option. Rent expense was $60,000, $55,379 and $55,378 for the years ended December 31, 2014, 2013 and 2012, respectively.

	Employee Agreements

	On April 28, 2014, the Company entered into amended and restated executive employment agreements (the “Employment Agreements”) with each of the following executive officers of the Company: H. Craig Dees, Ph.D. to serve as its Chief Executive Officer, Timothy C. Scott, Ph.D. to serve as its President, Eric A. Wachter, Ph.D. to serve as its Chief Technology Officer, and Peter R. Culpepper to serve as its Chief Financial Officer and Chief Operating Officer (collectively, the “executives”).

	Each Employment Agreement provides that such executive will be employed for an initial term of five years, subject to automatic renewal for successive one-year periods, unless the executive or the Company (i) terminates the Employment Agreement and the executive’s employment thereunder as provided in the Employment Agreement or (ii) provides notice of his or its intent not to renew. Each executive’s initial base salary is $500,000 per year, and any increases to such executive’s base salary shall be determined by the Compensation Committee of the Company’s Board of Directors in its sole discretion (the “Compensation Committee”). The executives are also eligible for annual bonuses and annual equity incentive awards as determined by the Compensation Committee in its sole discretion.

	Each of the Employment Agreements generally provides that in the event that the executive’s employment is terminated (i) voluntarily by the executive without Good Reason (as defined in the Employment Agreement), or (ii) by the Company for Cause (as defined in the Employment Agreement), the Company shall pay the executive’s compensation only through the last day of the employment period and, except as may otherwise be expressly provided, the Company shall have no further obligation to the executive. In the event that the executive’s employment is terminated by the Company other than for Cause (including death or disability), or if the executive voluntarily resigns for Good Reason, for so long as the executive is not in breach of his continuing obligations under the non-competition, non-solicitation and confidentiality restrictions contained in the Employment Agreement, the Company shall continue to pay the executive (or his estate) an amount equal to his base salary in effect immediately prior to the termination of his employment for a period of 24 months, to be paid in accordance with the Company’s regular payroll practices through the end of the fiscal year in which termination occurs and then in one lump sum payable to the executive in the first month of the calendar year following termination, as well as any prorated bonuses determined by the Compensation Committee, plus benefits on a substantially equivalent basis to those which would have been provided to the executive.

	During the term of each executive’s employment by the Company, and for a period of twenty-four (24) months following termination of employment, in the event that such executive voluntarily terminates his employment with the Company other than for Good Reason or such executive is terminated for Cause, then neither the executive nor any other person or entity with executive’s assistance shall (i) participate in any business that is directly competitive with the Company’s business or (ii) directly or indirectly, solicit any employee of the Company to quit or terminate their employment with the Company or employ as an employee, independent contractor, consultant, or in any other position, any person who was an employee of the Company or the Company’s affiliates within the preceding six months, subject to certain exceptions. In addition, without the express written consent of the Company, each executive shall not at any time (either during or after the termination of executive’s employment) use (other than for the benefit of the Company) or disclose to any other business entity proprietary or confidential information concerning the Company, any of their affiliates, or any of its officers. Neither shall such executive disclose any of the Company’s or the Company’s affiliates’ trade secrets or inventions of which he gained knowledge during his employment with the Company (subject to certain exceptions).

Equity_Transactions

Equity Transactions	12 Months Ended
Equity Transactions	Dec. 31, 2014
Text Block [Abstract]
Equity Transactions	3. Equity Transactions
	Common Stock Issued for Services
	(a) During the three months ended March 31, 2012, the Company issued 175,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $160,000. During the three months ended June 30, 2012, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $64,500. During the three months ended September 30, 2012, the Company issued 225,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $184,750. During the three months ended December 31, 2012, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $47,250. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value of stock at grant date.
	During the three months ended March 31, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $48,750. During the three months ended June 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $49,500. During the three months ended September 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $51,250. During the three months ended December 31, 2013, the Company issued 275,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $214,000. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value of stock at grant date.
	During the three months ended March 31, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $137,500. During the three months ended June 30, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $140,250. During the three months ended September 30, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $68,500. During the three months ended December 31, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $72,000. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value of stock at grant date.
	Warrants Issued for Services
	(b) During the three months ended March 31, 2012, the Company issued 1,003,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $475,668. During the three months ended March 31, 2012, 1,500 warrants expired. During the three months ended June 30, 2012, the Company issued 454,500 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $183,908. During the three months ended June 30, 2012, 4,368,644 warrants expired. During the three months ended September 30, 2012, the Company issued 1,732,135 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $721,753. During the three months ended September 30, 2012, 122,833 warrants expired. During the three months ended December 31, 2012, the Company issued 452,500 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $130,697. During the three months ended December 31, 2012, 987,667 warrants expired. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model. The fair market value for the warrants issued in 2012 ranged from $0.24 to $0.47 per warrant.
	During the three months ended March 31, 2013, the Company issued 1,924,973 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $409,640. During the three months ended March 31, 2013, 859,833 expired warrants were forfeited. During the three months ended June 30, 2013, the Company issued 2,605,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $931,655. During the three months ended June 30, 2013, 1,051,500 expired warrants were forfeited. During the three months ended September 30, 2013, the Company issued 442,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $186,223. During the three months ended September 30, 2013, 136,500 expired warrants were forfeited. During the three months ended December 31, 2013, the Company issued 209,473 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $259,306. During the three months ended December 31, 2013, 247,973 expired warrants were forfeited. During the three months ended December 31, 2013, 4,480,005 warrants were exercised on a cashless basis resulting in 2,386,004 shares being issued. During the three months ended December 31, 2013, 3,899,840 warrants were exercised for $3,412,392 resulting in 3,899,840 common shares issued. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value of the warrants, determined using the Black-Scholes option-pricing model. The fair market value for the warrants issued in 2013 ranged from $0.10 to $1.97 per warrant.

	During the three months ended March 31, 2014, the Company issued 733,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $900,317. During the three months ended March 31, 2014, 121,500 expired warrants were forfeited. During the three months ended March 31, 2014, 12,522,198 warrants were exercised on a cashless basis resulting in 9,100,824 common shares being issued. During the three months ended March 31, 2014, 3,036,218 warrants were exercised for $2,672,364 resulting in 3,036,218 common shares issued. During the three months ended June 30, 2014, the Company issued 202,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $450,002. During the three months ended June 30, 2014, 315,000 expired warrants were forfeited. During the three months ended June 30, 2014, 1,594,082 warrants were exercised on a cashless basis resulting in 915,467 common shares being issued. During the three months ended June 30, 2014, 372,000 warrants were exercised for $372,000 resulting in 372,000 common shares issued. During the three months ended September 30, 2014, the Company issued 6,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $4,189. During the three months ended September 30, 2014, 228,500 expired warrants were forfeited. During the three months ended December 31, 2014, the Company issued 1,503,913 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $966,819. During the three months ended December 31, 2014, 1,027,635 expired warrants were forfeited. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value of the warrants, determined using the Black-Scholes option-pricing model. The fair market value for the warrants issued in 2014 ranged from $0.55 to $2.56 per warrant.
	There are no provisions or obligations that would require the Company to cash settle any of its outstanding warrants. The equity classification of certain of the Company’s warrants is appropriate considering that these warrants provide the counterparties the right to purchase a fixed number of shares at a fixed price and the terms are not subject to any potential adjustment.
	Private Offerings of Common Stock and Warrants
	(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. At December 31, 2012, the Series A Warrants and the Series C Warrants exercise price of $1.12 per share was reduced to $0.675 per share due to a new issuance price, net of commissions, from a private offering of common stock and warrants to accredited investors during the three months ended December 31, 2012 and pursuant to their exercise price reset provision. For the year ended December 31, 2012 there was a gain recognized from the revaluation of the warrant liability of $495,338. During the three months ended December 31, 2013, 1,269,520 of the Series A Warrants were exercised. During the three months ended December 31, 2013, 748,663 of the Series C Warrants were exercised. The Company determined the fair value of the Series A and Series C Warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the Series A and Series C Warrants exercised of $1,620,081 was reclassified into additional paid-in capital. For the year ended December 31, 2013 there was a loss recognized from the revaluation of the warrant liability of $3,873,187. During the three months ended March 31, 2014, 858,825 of the Series A Warrants were exercised. During the three months ended March 31, 2014, 697,092 of the Series C Warrants were exercised. The Company determined the fair value of the Series A and Series C Warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the Series A and Series C Warrants exercised in 2014 of $3,911,370 was reclassified into additional paid-in capital. For the year ended December 31, 2014 there was a loss recognized from the revaluation of the warrant liability of $959,320.
	During the three months ended June 30, 2012 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,077,796. The Company accepted subscriptions, in the aggregate, for 1,855,176 shares of common stock, and five year warrants to purchase 1,855,176 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants was $1.12. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company issued five year fully vested warrants to purchase 371,035 shares of common stock with an exercise price of $1.12 to Network 1 Financial Securities, Inc., which represents 20% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended December 31, 2012 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,379,365. The Company accepted subscriptions, in the aggregate, for 3,172,486 shares of common stock, and five year warrants to purchase 3,172,486 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $279,317 and issued five year fully vested warrants to purchase 317,249 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended December 31, 2012, the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $710,000. The Company accepted subscriptions, in the aggregate, for 946,666 shares of common stock, and five year warrants to purchase 946,666 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Maxim Group LLC served as placement agent for the offering. In connection with the offering, the Company paid $97,300 and issued five year fully vested warrants to purchase 94,667 shares of common stock with an exercise price of $1.00 to Maxim Group LLC, which represents 10% of the total number of shares of common stock sold to investors solicited by Maxim Group LLC.
	During the three months ended March 31, 2013, the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,045,510. The Company accepted subscriptions, in the aggregate, for 5,394,013 shares of common stock, and five year warrants to purchase 7,277,264 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $522,640 and issued five year fully vested warrants to purchase 539,401 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended June 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,641,501. The Company accepted subscriptions, in the aggregate, for 3,522,001 shares of common stock, and five year warrants to purchase 5,283,003 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $314,173, accrued $32,500 at June 30, 2013 which was paid in July 2013 and issued five year fully vested warrants to purchase 352,200 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.
	During the three months ended September 30, 2013, the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,613,037. The Company accepted subscriptions, in the aggregate, for 6,150,718 shares of common stock and five year warrants to purchase 9,226,077 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $564,686 and issued five year fully vested warrants to purchase 615,072 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended September 30, 2013, the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,687,500. The Company accepted subscriptions, in the aggregate, for 3,583,333 shares of common stock and five year warrants to purchase 5,375,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Maxim Group LLC served as placement agent for the offering. In connection with the offering, the Company paid $349,375 and issued five year fully vested warrants to purchase 358,333 shares of common stock with an exercise price of $1.00 to Maxim Group LLC, which represents 10% of the total number of shares of common stock sold to investors solicited by Maxim Group LLC. During the three months ended December 31, 2013, the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $5,820,588. The Company accepted subscriptions, in the aggregate, for 7,760,784 shares of common stock and five year warrants to purchase 11,641,176 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company plans to use the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $747,302 and issued five year fully vested warrants to purchase 776,078 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended December 31, 2013, the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $1,312,500. The Company accepted subscriptions, in the aggregate, for 1,750,000 shares of common stock and five year warrants to purchase 2,625,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Maxim Group LLC served as placement agent for the offering. In connection with the offering, the Company paid $170,625 and issued five year fully vested warrants to purchase 175,000 shares of common stock with an exercise price of $1.00 to Maxim Group LLC, which represents 10% of the total number of shares of common stock sold to investors solicited by Maxim Group LLC.
	During the three months ended June 30, 2014, the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $5,000,000. The Company accepted subscriptions, in the aggregate, for 2,000,000 shares of common stock and five year warrants to purchase 2,000,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $3.00 per share. The purchase price for each share of common stock together with the warrants was $2.50. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $650,000 and issued five year fully vested warrants to purchase 300,000 shares of common stock with an exercise price of $2.50 to Network 1 Financial Securities, Inc., which represents 15% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended September 30, 2014, the Company commenced a private offering of up to $15 million of common stock and five-year warrants to accredited investors. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants is $1.00. The Company plans to use the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. is serving as placement agent for the offering. During the three months ended September 30, 2014, the Company received subscriptions, in the aggregate, for 3,586,300 shares of common stock and five year warrants to purchase 1,793,150 shares of common stock for an aggregate of $3,586,300. Investors will receive five year fully vested warrants to purchase up to 50% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants is $1.00. The Company plans to use the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. is serving as placement agent for the offering. In connection with the offering, the Company paid $466,219 and issued five year fully vested warrants to purchase 358,630 shares of common stock with an exercise price of $1.25 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock subscribed for by investors solicited by Network 1 Financial Securities, Inc. During the three months ended December 31, 2014, the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,198,300. The Company accepted subscriptions, in the aggregate, for 4,198,300 shares of common stock and five year warrants to purchase 2,099,150 shares of common stock. Investors received five year fully vested warrants to purchase up to 50% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants was $1.00. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $545,779 and issued five year fully vested warrants to purchase 419,830 shares of common stock with an exercise price of $1.25 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.
	Private Offering of Convertible Preferred Stock with Warrants
	(d) In March and April 2010, the Company issued 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the year ended December 31, 2012, there was a gain recognized from the revaluation of the warrant liability of $1,272,580. During the three months ended December 31, 2013, 1,146,662 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised of $765,997 was reclassified into additional paid-in capital. For the year ended December 31, 2013, there was a loss recognized from the revaluation of the warrant liability of $6,911,583. During the three months ended March 31, 2014, 1,756,665 of the warrants included in the warrant liability were exercised. During the three months ended June 30, 2014, 133,232 of the warrants included in the warrant liability were exercised. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $2,377,133 was reclassified into additional paid-in capital. For the year ended December 31, 2014, there was a gain recognized from the revaluation of the warrant liability of $4,222,519.
	Dividends on the 8% Convertible Preferred Stock accrued at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company has a deficit and, as a result, the dividends will be recorded against additional paid-in capital. In January 2012, the Company issued 64,183 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2012. At March 31, 2012, the Company recognized dividends of $50,631 which are included in dividends on preferred stock on the consolidated statement of operations. In April 2012, the Company issued 58,490 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 16, 2012. At June 30, 2012, the Company recognized dividends of $51,194 which are included in dividends on preferred stock on the consolidated statement of operations. In July 2012, the Company issued 61,424 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 16, 2012. At September 30, 2012, the Company recognized dividends of $43,884 which are included in dividends on preferred stock on the consolidated statement of operations. In October 2012, the Company issued 69,222 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of October 15, 2012. At December 31, 2012, the Company recognized dividends of $37,478 which are included in dividends on preferred stock on the consolidated statement of operations. In January 2013, the Company issued 61,022 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2013. At March 31, 2013, the Company recognized dividends of $21,921 which are included in dividends on preferred stock on the consolidated statement of operations. In April 2013, the Company issued 29,384 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 15, 2013. At June 30, 2013, the Company recognized dividends of $22,164 which are included in dividends on preferred stock on the consolidated statement of operations. In July 2013, the Company issued 34,598 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 15, 2013. At September 30, 2013, the Company recognized dividends of $10,586 which are included in dividends on preferred stock on the consolidated statement of operations. In October 2013, the Company issued 12,066 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of October 15, 2013. At December 31, 2013, the Company recognized no dividends due because of the full conversion of preferred stock to common stock as of December 31, 2013.
	During the three months ended March 31, 2012 there were 100,000 shares of the Company’s redeemable preferred stock that converted into 100,000 shares of the Company’s common stock. During the three months ended September 30, 2012 there were 490,000 shares of the Company’s redeemable preferred stock that converted into 490,000 shares of the Company’s common stock. During the three months ended December 31, 2012, there were 463,480 shares of the Company’s redeemable preferred stock that converted into 463,480 shares of the Company’s common stock. During the three months ended March 31, 2013, there were 593,000 shares of the Company’s redeemable preferred stock that converted into 593,000 shares of the Company’s common stock. During the three months ended June 30, 2013 there were 403,520 shares of the Company’s redeemable preferred stock that converted into 403,520 shares of the Company’s common stock. During the three months ended September 30, 2013, there were 734,999 shares of the Company’s redeemable preferred stock that converted into 734,999 shares of the Company’s common stock. During the three months ended December 31, 2013, there were 746,666 shares of the Company’s redeemable preferred stock that converted into 746,666 shares of the Company’s common stock. At December 31, 2013 there was no 8% Convertible Preferred Stock outstanding.
	(e) On February 22, 2013, the Company entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of an aggregate of $2,550,000 of Units at a purchase price of $0.75 per Unit. Each Unit consists of one share of Series A 8% Convertible Preferred Stock, par value $.001 per share, and a warrant to purchase one and one-quarter shares of the Company’s common stock, par value $.001 per share (subject to adjustment) at an exercise price of $1.00 per whole share (subject to adjustment). The total Series A 8% Convertible Preferred Stock issued was 3,400,001 shares, and the total warrants were 4,250,000. The Company used the net proceeds of the private placement for working capital, FDA trials, securing licensing partnerships, and general corporate purposes.

	The Company determined that warrants issued in February, 2013 with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share.
	The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred stock on the consolidated statements of operations.
	The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. During the three months ended December 31, 2013, 2,400,000 of the warrants included in the warrant liability were exercised, resulting in 2,400,000 common shares being issued. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised of $2,016,000 was reclassified into additional paid-in capital. For the year ended December 31, 2013, there was a loss recognized from the revaluation of the warrant liability of $3,886,360. During the three months ended March 31, 2014, 1,650,000 of the warrants included in the warrant liability were exercised. During the three months ended June 30, 2014, 200,000 of the warrants included in the warrant liability were exercised, which is the remainder of the 2013 warrants. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $4,047,116 was reclassified into additional paid-in capital. For the year ended December 31, 2014, there was a loss recognized from the revaluation of the warrant liability of $878,806.
	Dividends on the Series A 8% Convertible Preferred Stock accrued at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company paid the dividends in common stock although was required to pay the initial dividends due in cash. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063 which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860 which are included in dividends on preferred stock on the consolidated statement of operations. In July 2013, the Company issued 79,401 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 15, 2013. At September 30, 2013, the Company recognized dividends of $28,104 which are included in dividends on preferred stock on the consolidated statement of operations. In October 2013, the Company issued 32,033 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of October 15, 2013. At December 31, 2013, the Company recognized no dividends due because of the full conversion of preferred stock to common stock as of January 15, 2014. In 2014, the Company recognized no dividends because of the conversion of all outstanding preferred stock to common stock as of January 15, 2014.
	During the three months ended September 30, 2013, there were 441,667 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 441,667 shares of the Company’s common stock. During the three months ended December 31, 2013, there were 2,925,000 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 2,925,000 shares of the Company’s common stock. In January 2014, there were 33,334 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 33,334 shares of the Company’s common stock. As of January 15, 2014, there were no shares of Series A 8% Convertible Preferred Stock outstanding.
	Common Stock Purchase Agreements
	(f) In December 2010, we entered into a purchase agreement with Lincoln Park Capital Fund, LLC, pursuant to which the Company could, in our sole discretion, direct Lincoln Park to purchase up to an additional $30,000,000 of our common stock over the 30-month term of the purchase agreement at no less than $0.75 per share. On June 23, 2013, our agreement with Lincoln Park Capital Fund, LLC expired.

	On July 22, 2013 the Company entered into a Purchase Agreement with Alpha Capital Anstalt pursuant to which the Company may, in the Company’s sole discretion, direct the purchase up to $30,000,000 of the Company’s common stock over the 30-month term of the Purchase Agreement. From time to time during the term of the Purchase Agreement, the Company may, in its sole discretion direct the purchase up to 100,000 shares of the Company’s common stock at a per share purchase price equal to the lesser of (i) the lowest sale price of the Company’s common stock reported on the OTCQB or NYSE MKT on the purchase date and (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 12 consecutive business days ending on the business day immediately preceding the purchase date. The Company may, under certain circumstances, at its discretion, increase the amount of common stock that it sells on each purchase date. The committed obligation under any single regular purchase shall not exceed $250,000, unless the parties mutually agree to increase the dollar amount of any regular purchase. In no event may Alpha Capital Anstalt purchase shares of the Company’s common stock for less than $0.75 per share. In consideration of entering into the Purchase Agreement and making the commitment to purchase the Purchase Shares, the Company issued 250,000 shares of the Company’s common stock to Alpha Capital Anstalt. Costs charged to operations for this commitment fee were $162,500. The Purchase Agreement may be terminated by the Company at any time, at its discretion, without cost to the Company. As of December 31, 2014, the Company had the full amount of the Purchase Agreement available for use.

Stock_Incentive_Plan_and_Warra

Stock Incentive Plan and Warrants	12 Months Ended
Stock Incentive Plan and Warrants	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Incentive Plan and Warrants	4. Stock Incentive Plan and Warrants
	Options
	The Company maintained two long-term incentive compensation plans which have been terminated; namely, the Provectus Pharmaceuticals, Inc. 2002 Stock Plan, which provided for the issuance of 18,450,000 shares of common stock pursuant to stock options, and the 2012 Stock Plan, which provided for the issuance of up to 20,000,000 shares of common stock pursuant to stock options. Currently, the Provectus Biopharmaceuticals, Inc. 2014 Equity Compensation Plan provides for the issuance of up to 20,000,000 shares of common stock pursuant to stock options for the benefit of eligible employees and directors of the Company.
	Options granted under the 2002, 2012 and 2014 Stock Plans were either “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code or options which were not incentive stock options. The stock options are exercisable over a period determined by the Board of Directors (through its Compensation Committee), but generally no longer than 10 years after the date they are granted.
	For stock options granted to employees during 2014, 2013 and 2012, the Company has estimated the fair value of each option granted using the Black-Scholes option pricing model with the following assumptions:


			2014		2013		2012
	Weighted average fair value per options granted		$0.77		$0.57		$0.73
	Significant assumptions (weighted average) risk-free interest rate at grant date		0.25%		0.25%		0.25%
	Expected stock price volatility		85% – 92%		83% – 85%		83% – 87%
	Expected option life (years)		10		10		10
	On May 14, 2012, the Company issued 50,000 stock options to a newly appointed member of the board. On June 28, 2012, the Company issued 200,000 stock options to its re-elected members of the board. All of the stock options issued in 2012 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance.
	One employee of the Company exercised 18,750 options at an exercise price of $0.32 per share of common stock for $6,000 and 25,000 options at an exercise price of $0.60 per share of common stock for $15,000 during the three months ended June 30, 2013. One former non-employee member of the board forfeited 25,000 stock options on May 29, 2013. On August 19, 2013, the Company issued 250,000 stock options to its re-elected members of the board. All of the stock options issued in 2013 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance.
	One employee of the Company exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750, 14,248 options at an exercise price of $0.75 per share of common stock for $10,686 and 600,000 options at an exercise price of $0.93 per share of common stock for $558,000 during the three months ended March 31, 2014. Another employee of the Company exercised 300,000 options at an exercise price of $1.10 per share of common stock for $330,000 during the three months ended March 31, 2014. Another employee of the Company exercised 189,624 options at an exercise price of $1.10 per share of common stock for $208,586 during the three months ended March 31, 2014. One employee of the Company forfeited 300,000 stock options on February 26, 2014. One employee of the Company exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750 during the three months ended June 30, 2014. Another employee of the Company exercised 100,000 options at an exercise price of $1.25 per share of common stock for $125,000 during the three months ended June 30, 2014. A former non-employee member of the board of directors exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750 during the three months ended June 30, 2014. One employee of the Company forfeited 25,000 stock options on May 27, 2014. On July 29, 2014, the Company issued a total of 150,000 stock options to its three re-elected non-employee members of the board of directors. All of the stock options issued in 2014 vested on the date of grant and have an exercise price equal to the fair market price on the date of issuance. One employee of the Company exercised 96,875 options at an exercise price of $0.64 per share of common stock for $62,000, and 126,361 options at an exercise price of $0.64 per share of common stock for $80,871 during the three months ended December 31, 2014. Three employees of the Company had fully vested options rescinded during the three months ended December 31, 2014 due to the terms of the settlement discussed in Note 9.
	The compensation cost relating to share-based payment transactions is measured based on the fair value of the equity or liability instruments issued. For purposes of estimating the fair value of each stock option on the date of grant, the Company utilized the Black-Scholes option-pricing model. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option-pricing models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock (as determined by reviewing its historical public market closing prices). Included in the results for the year ended December 31, 2014, is $115,645 of stock-based compensation expense which relates to the fair value of stock options vested in 2014. Included in the results for the year ended December 31, 2013, is $142,310 of stock-based compensation expense which relates to the fair value of stock options vested in 2013. Included in the results for the year ended December 31, 2012, is $183,028 of stock-based compensation expense which relates to the fair value of stock options vested in 2012.
	The following table summarizes the options granted, exercised, outstanding and exercisable as of December 31, 2012, 2013 and 2014:


			Shares				Exercise Price			Weighted
							Per Share			Average
										Exercise
										Price
	Outstanding at January 1, 2012			14,890,956			$	0.32 – 1.50		$	0.98
	Granted			250,000			$	0.84 – 0.93		$	0.86
	Exercised			—				—			—
	Forfeited			—				—			—

	Outstanding and exercisable at December 31, 2012			15,140,956			$	0.32 – 1.50		$	0.97

	Outstanding at January 1, 2013			15,140,956			$	0.32 – 1.50		$	0.97
	Granted			250,000			$	0.67		$	0.67
	Exercised			(43,750	)		$	0.32 – 0.60		$	0.48
	Forfeited			(25,000	)		$	0.6		$	0.6

	Outstanding and exercisable at December 31, 2013			15,322,206			$	0.62 – 1.50		$	0.97

	Outstanding at January 1, 2014			15,322,206			$	0.62 – 1.50		$	0.97
	Granted			150,000			$	0.88		$	0.88
	Settlement			(2,800,000	)		$	0.93 – 1.00		$	0.97
	Exercised			(1,502,108	)		$	0.64 – 1.25		$	0.96
	Forfeited			(325,000	)		$	0.95 – 1.10		$	1.09

	Outstanding and exercisable at December 31, 2014			10,845,098			$	0.64 – 1.50		$	0.97


	The following table summarizes information about stock options outstanding at December 31, 2014 in order of issuance from oldest to newest.


	Exercise Price		Number				Weighted			Outstanding		Number			Exercisable
			Outstanding				Average			Weighted		Exercisable			Weighted
			at December 31,				Remaining			Average		at December 31,			Average
			2014				contractual			Exercise price		2014			Exercise
							Life								Price
	$0.64			376,764				0.00 years		$	0.64		376,764		$	0.64
	$0.75			708,334				0.42 years		$	0.75		708,334		$	0.75
	$0.94			575,000				0.92 years		$	0.94		575,000		$	0.94
	$1.02			4,135,000				1.50 years		$	1.02		4,135,000		$	1.02
	$1.50			200,000				2.50 years		$	1.5		200,000		$	1.5
	$1.16			50,000				3.42 years		$	1.16		50,000		$	1.16
	$1.00			150,000				3.50 years		$	1		150,000		$	1
	$1.04			250,000				4.50 years		$	1.04		250,000		$	1.04
	$1.16			250,000				5.50 years		$	1.16		250,000		$	1.16
	$1.00			1,600,000				5.50 years		$	1		1,600,000		$	1
$1.04			250,000				6.50 years		$	1.04		250,000		$	1.04
$0.99			50,000				6.50 years		$	0.99		50,000		$	0.99
$0.93			1,600,000				6.67 years		$	0.93		1,600,000		$	0.93
$0.93			50,000				7.38 years		$	0.93		50,000		$	0.93
$0.84			200,000				7.50 years		$	0.84		200,000		$	0.84
$0.67			250,000				8.71 years		$	0.67		250,000		$	0.67
$0.88			150,000				9.67 years		$	0.88		150,000		$	0.88

			10,845,098				3.85 years		$	0.97		10,845,098		$	0.97

The total intrinsic value of options exercised during the year ended December 31, 2014 which were in the money was $1,327,300.
The total intrinsic value of options exercised during the year ended December 31, 2013 which were in the money was $7,000.
There were no options exercised during the year ended December 31, 2012.
The following is a summary of nonvested stock option activity for the year ended December 31, 2014:


		Number of Shares				Weighted Average
		Number of Shares				Grant-Date Fair Value
Nonvested at December 31, 2013			—			$	—
Granted			150,000			$	0.77
Vested			(150,000	)		$	0.77
Canceled			—				—

Nonvested at December 31, 2014			—			$	—

As of December 31, 2014, there was no unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the Plan.

The following is a summary of the aggregate intrinsic value of shares outstanding and exercisable at December 31, 2014. The aggregate intrinsic value of stock options outstanding and exercisable is defined as the difference between the market value of the Company’s stock as of the end of the period and the exercise price of the stock options which are in the money.


		Number of Shares				Aggregate Intrinsic
		Number of Shares				Value
Outstanding and Exercisable at December 31, 2014			10,845,098			$	128,199

Warrants
The following table summarizes the warrants granted, exercised, outstanding and exercisable as of December 31, 2012, 2013 and 2014.


		Warrants				Exercise Price			Weighted Average
		Warrants				Per Warrant			Exercise Price
Outstanding at January 1, 2012			25,119,247			$	0.91 – 2.00		$	1.15
Granted			10,399,414			$	0.68 – 1.50		$	1
Exercised			—				—			—
Forfeited			(5,480,644	)		$	0.91 – 1.50		$	1.29

Outstanding and exercisable at December 31, 2012			30,038,017			$	0.68 – 2.00		$	1.05

Outstanding at January 1, 2013			30,038,017			$	0.68 – 2.00		$	1.05
Granted			53,675,050			$	0.68 – 1.12		$	1
Exercised			(8,379,845	)		$	0.68 – 1.25		$	0.93
Forfeited			(2,295,806	)		$	0.68 – 1.12		$	0.87

Outstanding and exercisable at December 31, 2013			73,037,416			$	0.68 – 2.00		$	1.03

Outstanding at January 1, 2014			73,037,416			$	0.68 – 2.00		$	1.03
Granted			9,415,673			$	1.00 – 3.00		$	1.61
Exercised			(17,524,498	)		$	0.68 – 1.50		$	1.01
Forfeited			(1,692,635	)		$	0.95 – 1.25		$	1.07

Outstanding and exercisable at December 31, 2014			63,235,956			$	0.68 – 3.00		$	1.12

The following table summarizes information about warrants outstanding at December 31, 2014.


Exercise Price		Number Outstanding				Weighted Average			Weighted Average
		and Exercisable at				Remaining			Exercise Price
		December 31, 2014				Contractual Life in
						Years
$0.68			134,994				1		$	0.68
$0.95			187,467				0		$	0.95
$1.00			48,844,755				3.3		$	1
$1.12			1,793,036				1.42		$	1.12
$1.25			8,782,703				2.98		$	1.25
$1.50			670,001				1.3		$	1.5
$1.75			200,000				1		$	1.75
$2.00			323,000				2.25		$	2
$2.50			300,000				4.33		$	2.5
$3.00			2,000,000				4.33		$	3

			63,235,956				3.19		$	1.12

Related_Party_Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	5. Related Party Transactions

	The Company paid one non-employee member of the board $54,000 for consulting services performed as of December 31, 2012. The Company paid another non-employee member of the board $75,000 for consulting services performed as of December 31, 2012 and issued 100,000 fully vested warrants in exchange for services. Consulting costs charged to operations were $47,520 for the services for which these warrants were issued. As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model. The Company paid a third non-employee member of the board $75,000 for consulting services performed as of December 31, 2012.

	The Company paid one non-employee member of the board $54,000 for consulting services performed as of December 31, 2013. The Company paid another non-employee member of the board $75,000 for consulting services performed as of December 31, 2013. The Company paid a third non-employee member of the board $75,000 for consulting services performed as of December 31, 2013.

	The Company paid one of the Company’s directors $6,000 as of March 31, 2014, all of which was paid as part of his overall compensation of an aggregate of $85,000 for board and committee service.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes
	Reconciliations between the statutory federal income tax rate and the Company’s effective tax rate follow:


		2014						2013						2012
	Years Ended December 31,	Amount			%			Amount			%			Amount			%
	Federal statutory rate	$	(3,483,000	)		(34.0	)	$	(9,417,000	)		(34.0	)	$	(4,273,000	)		(34.0	)
	State taxes		(461,000	)		(4.5	)		(1,246,000	)		(4.5	)		(566,000	)		(4.5	)
	Adjustment to valuation allowance		4,862,000			47.7			5,015,000			18.1			4,596,000			36.5
	Non-deductible compensation		—			—			—			—			924,000			7
	(Gain) loss on warrant liability		(918,000	)		(9.2	)		5,648,000			20.4			(681,000	)		(5.0	)

	Actual tax benefit	$	—			—		$	—			—		$	—			—

	The components of the Company’s deferred income taxes are summarized below:


	December 31,	2014			2013
	Deferred tax assets
	Net operating loss carry-forwards	$	34,046,000		$	30,995,000
	Stock-based compensation		6,344,000			6,299,000
	Warrants for services		5,421,000			4,527,000

	Deferred tax asset		45,811,000			41,821,000
	Deferred tax liabilities
	Patent amortization		(1,380,000	)		(1,638,000	)
	Valuation allowance		(44,431,000	)		(40,183,000	)

	Net deferred taxes	$	—		$	—

	A valuation allowance against deferred tax assets is required if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets may not be realized. The Company is in the development stage and realization of the deferred tax assets is not considered more likely than not. As a result, the Company has recorded a full valuation allowance for the net deferred tax assets.
	Since inception of the Company on January 17, 2002, the Company has generated tax net operating losses of approximately $99 million, expiring in 2022 through 2034. The tax loss carry-forwards of the Company may be subject to limitation by Section 382 of the Internal Revenue Code with respect to the amount utilizable each year. This limitation reduces the Company’s ability to utilize net operating loss carry-forwards. The amount of the limitation has been quantified by the Company. The Company completed a Section 382 study for the period from inception through the year ended December 31, 2014 and recorded a limitation of $3.2 million of their net operating loss carry-forward.

	The Company has determined that there are no uncertain tax positions as of December 31, 2014 or 2013 and does not expect any significant change within the next year.

401K_Profit_Sharing_Plan

401(K) Profit Sharing Plan	12 Months Ended
401(K) Profit Sharing Plan	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
401(K) Profit Sharing Plan	7. 401(K) Profit Sharing Plan

	Contributions made by the Company in 2012 totaled approximately $132,000 and were included in other accrued expenses. Contributions made by the Company in 2013 totaled approximately $226,000. Contributions made by the Company in 2014 totaled approximately $320,000.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

8. Fair Value of Financial Instruments

The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are measured and reported on a fair value basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. The fair value of certain of the Company’s financial instruments, including Cash and cash equivalents, short-term receivable and Accounts payable, approximates the carrying value due to the relatively short maturity of such instruments. The fair value of derivative instruments is determined by management with the assistance of an independent third party valuation specialist. The warrant liability is a derivative instrument and is classified as Level 3. The Company used the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used are as follows:

December 31, 2014

December 31, 2013

December 31, 2012

2010 Warrants:

Weighted average term

0.2 years

1.2 years

2.2 years

Probability the warrant exercise price would be reset

Volatility

63.70%

66.5% to 69.5%

58.9% to 63.4%

Risk free interest rate

0.03% to 0.04%

0.13% to 0.38%

0.25% to 0.36%

2011 Warrants:

Weighted average term

1.0 years

2.0 years

3.0 years

Probability the warrant exercise price would be reset

Volatility

159.20%

64.70%

58.9% to 63.4%

Risk free interest rate

0.25%

0.38% to 0.78%

0.25% to 0.36%

2013 Warrants:

Weighted average term

N/A

4.1 years

N/A

Probability the warrant exercise price would be reset

N/A

Volatility

N/A

67.20%

N/A

Risk free interest rate

N/A

0.78% to 1.78%

N/A

At December 31, 2014, there are no remaining 2013 warrants and therefore no associated warrant liability.

The warrant liability measured at fair value on a recurring basis is as follows:

Total

Level 1

Level 2

Level 3

Derivative instruments:

Warrant liability at December 31, 2014

146,560

—

146,560

Warrant liability at December 31, 2013

12,866,572

—

12,866,572

A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2013 to December 31, 2014 is as follows:

Balance at January 1, 2013

1,299,570

Issuance of warrants

1,297,950

Net loss included in earnings

14,671,130

Exercise of warrants

(4,402,078

)

Balance at December 31, 2013

12,866,572

Balance at January 1, 2014

12,866,572

Issuance of warrants

—

Net gain included in earnings

(2,384,393

)

Exercise of warrants

(10,335,619

)

Balance at December 31, 2014

146,560

Litigation

Litigation	12 Months Ended
Litigation	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Litigation	9. Litigation

	Kleba Shareholder Derivative Lawsuit

	On January 2, 2013, Glenn Kleba, derivatively on behalf of the Company, filed a shareholder derivative complaint in the Circuit Court for the State of Tennessee, Knox County (the “Court”), against H. Craig Dees, Timothy C. Scott, Eric A. Wachter, and Peter R. Culpepper (collectively, the “Executives”), Stuart Fuchs, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, together with the Executives, the “Individual Defendants”), and against the Company as a nominal defendant (the “Shareholder Derivative Lawsuit”). The Shareholder Derivative Lawsuit alleged (i) breach of fiduciary duties, (ii) waste of corporate assets, and (iii) unjust enrichment, all three claims based on Mr. Kleba’s allegations that the defendants authorized and/or accepted stock option awards in violation of the terms of the Company’s 2002 Stock Plan (the “Plan”) by issuing stock options in excess of the amounts authorized under the Plan and delegated to defendant H. Craig Dees the sole authority to grant himself and the other Executives cash bonuses that Mr. Kleba alleges to be excessive.

	In April 2013, the Company’s Board of Directors appointed a special litigation committee to investigate the allegations of the Shareholder Derivative Complaint and make a determination as to how the matter should be resolved. The special litigation committee conducted its investigation, and proceedings in the case were stayed pending the conclusion of the committee’s investigation. The Company has established a reserve of $100,000 for potential liabilities because such is the amount of the self-insured retention of its insurance policy. On February 21, 2014, an Amended Shareholder Derivative Complaint was filed which added Don B. Dale (“Mr. Dale”) as a plaintiff.

	On March 6, 2014, the Company filed a Joint Notice of Settlement (the “Notice of Settlement”) in the Shareholder Derivative Lawsuit. In addition to the Company, the parties to the Notice of Settlement are Mr. Kleba, Mr. Dale and the Individual Defendants.

	On June 6, 2014, the Company, in its capacity as a nominal defendant, entered into a Stipulated Settlement Agreement and Mutual Release (the “Settlement”) in the Shareholder Derivative Lawsuit. In addition to the Company and the Individual Defendants, Plaintiffs Glenn Kleba and Don B. Dale are parties to the Settlement.

	By entering into the Settlement, the settling parties have resolved the derivative claims to their mutual satisfaction. The Individual Defendants have not admitted the validity of any claims or allegations and the settling plaintiffs have not admitted that any claims or allegations lack merit or foundation. Under the terms of the Settlement, (i) the Executives each agreed (A) to re-pay to the Company $2.24 Million of the cash bonuses they each received in 2010 and 2011, which amount equals 70% of such bonuses or an estimate of the after-tax net proceeds to each Executive; provided, however, that subject to certain terms and conditions set forth in the Settlement, the Executives are entitled to a 2:1 credit such that total actual repayment may be $1.12 Million each; (B) to reimburse the Company for 25% of the actual costs, net of recovery from any other source, incurred by the Company as a result of the Shareholder Derivative Lawsuit; and (C) to grant to the Company a first priority security interest in 1,000,000 shares of the Company’s common stock owned by each such Executive to serve as collateral for the amounts due to the Company under the Settlement; (ii) Drs. Dees and Scott and Mr. Culpepper agreed to retain incentive stock options for 100,000 shares but shall forfeit 50% of the nonqualified stock options granted to each such Executive in both 2010 and 2011. The Settlement also requires that each of the Executives enter into new employment agreements with the Company, which were entered into on April 28, 2014, and that the Company adhere to certain corporate governance principles and processes in the future. Under the Settlement, Messrs. Fuchs and Smith and Dr. McMasters have each agreed to pay the Company $25,000 in cash, subject to reduction by such amount that the Company’s insurance carrier pays to the Company on behalf of such defendant pursuant to such defendant’s directors and officers liability insurance policy. The Settlement also provides for an award to plaintiffs’ counsel of attorneys’ fees and reimbursement of expenses in connection with their role in this litigation, subject to Court approval.

	On July 24, 2014, the Court approved the terms of the proposed Settlement and awarded $911,000 to plaintiffs’ counsel for attorneys’ fees and reimbursement of expenses in connection with their role in the Shareholder Derivative Lawsuit. The payment to plaintiff’s counsel was made by the Company during October 2014 and is recorded as other current assets at December 31, 2014. The Company is seeking reimbursement of the full amount from insurance and if the full amount is not received from insurance, the amount remaining will be reimbursed to the Company from the Individual Defendants.

	On October 3, 2014, the Settlement was effective and stock options for Drs. Dees and Scott and Mr. Culpepper were rescinded, totaling 2,800,000. At December 31, 2014, a Gain on Settlement of $4,178,345, net of discount, was recorded for the total due from the Executives. A Short-term Receivable was recorded for $733,333 and a Long-term Receivable was recorded for $3,378,345. A discount for implied interest of $301,655 was recorded as an offset to the Gain on Settlement in the consolidated statements of operations. $66,667 was repaid by the Executives as of December 31, 2014. The cash settlement amounts will be repaid to the Company over a period of five years with the first payment due in October 2015 and the final payment is expected to be received by October 3, 2019.

	Class Action Lawsuits

	On May 27, 2014, Cary Farrah and James H. Harrison, Jr., individually and on behalf of all others similarly situated (the “Farrah Case”), and on May 29, 2014, each of Paul Jason Chaney, individually and on behalf of all others similarly situated (the “Chaney Case”), and Jayson Dauphinee, individually and on behalf of all others similarly situated (the “Dauphinee Case”) (the plaintiffs in the Farrah Case, the Chaney Case and the Dauphinee Case collectively referred to as the “Plaintiffs”), each filed a class action lawsuit in the United States District Court for the Middle District of Tennessee against the Company, H. Craig Dees, Timothy C. Scott and Peter R. Culpepper (the “Defendants”) alleging violations by the Defendants of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. Specifically, the Plaintiffs in each of the Farrah Case, the Chaney Case and the Dauphinee Case allege that the Defendants are liable for making false statements and failing to disclose adverse facts known to them about the Company, in connection with the Company’s application to the FDA for Breakthrough Therapy Designation (“BTD”) of the Company’s melanoma drug, PV-10, in the Spring of 2014, and the FDA’s subsequent denial of the Company’s application for BTD. The Company intends to defend vigorously against all claims in these complaints. However, in view of the inherent uncertainties of litigation and the early stage of this litigation, the outcome of these cases cannot be predicted at this time. Likewise, the amount of any potential loss cannot be reasonably estimated. No amounts have been recorded in the consolidated financial statements as the outcome of these cases cannot be predicted and the amount of any potential loss is not estimable at this time.

	On July 9, 2014, the Plaintiffs and the Defendants filed joint motions in the Farrah Case, the Chaney Case and the Dauphinee Case to consolidate the cases and transfer them to United States District Court for the Eastern District of Tennessee. By order dated July 16, 2014, the United States District Court for the Middle District of Tennessee entered an order consolidating the Farrah Case, the Chaney Case and the Dauphinee Case (collectively and, as consolidated, the “Securities Litigation”) and transferred the Securities Litigation to the United States District Court for the Eastern District of Tennessee.

	On November 26, 2014, the United States District Court for the Eastern District of Tennessee (the “Court”) entered an order appointing Fawwaz Hamati as the Lead Plaintiff in the Securities Litigation, with the Law Firm of Glancy Binkow & Goldberg, LLP as counsel to Lead Plaintiff. On February 3, 2015, the Court entered an order compelling the Lead Plaintiff to file a consolidated amended complaint within 60 days of entry of the order. As of March 4, 2015, the Lead Plaintiff has yet to file a consolidated amended complaint.



	Hurtado Shareholder Derivative Lawsuit

	On June 4, 2014, Karla Hurtado, derivatively on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the Middle District of Tennessee against H. Craig Dees, Timothy C. Scott, Jan E. Koe, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, the “Individual Defendants”), and against the Company as a nominal defendant (the “Hurtado Shareholder Derivative Lawsuit”). The Hurtado Shareholder Derivative Lawsuit alleges (i) breach of fiduciary duties and (ii) abuse of control, both claims based on Ms. Hurtado’s allegations that the Individual Defendants (a) recklessly permitted the Company to make false and misleading disclosures and (b) failed to implement adequate controls and procedures to ensure the accuracy of the Company’s disclosures.

	On July 25, 2014, the United States District Court for the Middle District of Tennessee entered an order transferring the case to the United States District Court for the Eastern District of Tennessee and, in light of the pending Securities Litigation, relieving the Individual Defendants from responding to the complaint in the Hurtado Shareholder Derivative Lawsuit pending further order from the United States District Court for the Eastern District of Tennessee.

	As a nominal defendant, no relief is sought against the Company itself in the Hurtado Shareholder Derivative Lawsuit.

	Montiminy Shareholder Derivative Lawsuit

	On October 24, 2014, Paul Montiminy brought a shareholder derivative complaint on behalf of the Company in the United States District Court for the Eastern District of Tennessee (the “Montiminy Shareholder Derivative Lawsuit”) against H. Craig Dees, Timothy C. Scott, Jan E. Koe, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, the “Individual Defendants”). Like the Hurtado Shareholder Derivative Lawsuit, the Montiminy Shareholder Derivative Lawsuit alleges (i) breach of fiduciary duties and (ii) gross mismanagement of the assets and business of the Company, both claims based on Mr. Montiminy’s allegations that the Individual Defendants recklessly permitted the Company to make certain false and misleading disclosures regarding the likelihood that the Company’s melanoma drug, PV-10, would qualify for BTD. As a practical matter, the factual allegations and requested relief in the Montiminy Shareholder Derivative Lawsuit are substantively the same as those in the Hurtado Shareholder Derivative Lawsuit.

	On December 29, 2014, the United States District Court for the Eastern District of Tennessee (the “Court”) entered an order consolidating the Hurtado Shareholder Derivative Lawsuit and the Montiminy Derivative Lawsuit. On February 25, 2015, the parties submitted a proposed agreed order staying the Hurtado and Montiminy Shareholder Derivative Lawsuits until the Court issues a ruling on the anticipated motion to dismiss the amended consolidated complaint to be filed in the Securities Litigation. As of March 4, 2015, the Court has not yet entered the proposed agreed order staying the Hurtado and Montiminy Shareholder Derivative Lawsuits.

	Again, as in the Hurtado Shareholder Derivative Lawsuit, no relief is sought against the Company itself; the action is against the Individual Defendants only.

	Foley Shareholder Derivative Complaint

	On October 28, 2014, Chris Foley, derivatively on behalf of the Company, filed a shareholder derivative complaint in the Chancery Court of Knox County, Tennessee against H. Craig Dees, Timothy C. Scott, Jan E. Koe, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, the “Individual Defendants”), and against the Company as a nominal defendant (the “Foley Shareholder Derivative Lawsuit”). The Foley Shareholder Derivative Lawsuit was brought by the same attorney as the Montiminy Shareholder Derivative Lawsuit, Paul Kent Bramlett of Bramlett Law Offices. Other than the difference in the named plaintiff, the complaints in the Foley Shareholder Derivative Lawsuit and the Montiminy Shareholder Derivative Lawsuit are identical. Since the filing of the Foley Shareholder Derivative Lawsuit, the parties have submitted a proposed agreed order staying the Foley Derivative Lawsuit until the United States District Court for the Eastern District of Tennessee issues a ruling on the anticipated motion to dismiss the amended consolidated complaint to be filed in the Securities Litigation.

Subsequent_Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events

	The Company has evaluated subsequent events through the date of the filing of these financial statements.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
Selected Quarterly Financial Data (Unaudited)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (Unaudited)	11. Selected Quarterly Financial Data (Unaudited)
	The following tables present a summary of quarterly results of operations for 2014 and 2013:


		Three Months Ended
		March 31,			June 30,			September 30,			December 31,
		2014			2014			2014			2014
		(in thousands, except per share data)
	Consolidated Statement of Operations Data:
	Gain on settlement – net of discount	$	—		$	—		$	—		$	4,178
	Total operating loss not including gain on settlement		(4,382	)		(4,160	)		(3,826	)		(4,443	)
	Other income (expense), net		(2,285	)		3,517			77			1,081

	Net income (loss)		(6,667	)		(643	)		(3,749	)		816

	Net income (loss) applicable to common stockholders	$	(6,667	)	$	(643	)	$	(3,749	)	$	816

	Basic and diluted income (loss) per common share	$	(0.04	)	$	(0.00	)	$	(0.02	)	$	0
	Weighted average number of common shares outstanding – basic and diluted		168,860			175,554			179,089			182,057


		Three Months Ended
		March 31,			June 30,			September 30,			December 31,
		2013			2013			2013			2013
		(in thousands, except per share data)
	Consolidated Statement of Operations Data:
	Total operating loss	$	(3,247	)	$	(3,287	)	$	(3,650	)	$	(2,844	)
	Other income (expense), net		(923	)		909			(903	)		(13,754	)

	Net loss		(4,170	)		(2,378	)		(4,553	)		(16,598	)
	Dividends on preferred stock		(1,077	)		(72	)		(38	)		—

	Net loss applicable to common stockholders	$	(5,247	)	$	(2,450	)	$	(4,591	)	$	(16,598	)

	Basic and diluted loss per common share	$	(0.04	)	$	(0.02	)	$	(0.03	)	$	(0.11	)
	Weighted average number of common shares outstanding – basic and diluted		120,702			127,115			131,574			148,314

Organization_and_Significant_A1

Organization and Significant Accounting Policies (Policies)	12 Months Ended
Organization and Significant Accounting Policies (Policies)	Dec. 31, 2014
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations

	Provectus Biopharmaceuticals, Inc. (together with its subsidiaries, the “Company”) is a biopharmaceutical company that is focusing on developing minimally invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer including melanoma, breast cancer, and cancers of the liver. To date, the Company has no revenues from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates, or sell or license the Company’s OTC products or non-core technologies.
Principles of Consolidation	Principles of Consolidation
Principles of Consolidation	Intercompany balances and transactions have been eliminated in consolidation.
Estimates	Estimates
Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents
Cash and Cash Equivalents	The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
Cash Concentrations	Cash Concentrations

	Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits of $250,000 although the Company seeks to minimize this through treasury management. We have never experienced any losses related to these balances.
Reclassification of Prior Period Balances	Reclassification of Prior Period Balances
Reclassification of Prior Period Balances	Certain reclassifications have been made to prior period amounts to conform to current-year presentation.
Equipment and Furnishings	Equipment and Furnishings

	Equipment and furnishings are stated at cost. Depreciation of equipment is provided for using the straight-line method over the estimated useful lives of the assets. Computers and laboratory equipment are being depreciated over five years; furniture and fixtures are being depreciated over seven years.
Long-Lived Assets	Long-Lived Assets
Long-Lived Assets	The Company reviews the carrying values of its long-lived assets for possible impairment whenever an event or change in circumstances indicates that the carrying amount of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less cost to sell. Management has determined there to be no impairment.
Patent Costs	Patent Costs

	Internal patent costs are expensed in the period incurred. Patents purchased are capitalized and amortized over the remaining life of the patent.

	Patents at December 31, 2014 were acquired as a result of the merger with Valley Pharmaceuticals, Inc. (“Valley”) on November 19, 2002. The majority stockholders of Provectus also owned all of the shares of Valley and therefore the assets acquired from Valley were recorded at their carry-over basis. The patents are being amortized over the remaining lives of the patents, which range from 2-7 years at December 31, 2014. Annual amortization of the patents is expected to approximate $671,000 for each of the next two years, $659,000 in 2017 and 2018, and $547,000 in 2019.
Research and Development	Research and Development
Research and Development	Research and development costs are charged to expense when incurred. An allocation of payroll expenses to research and development is made based on a percentage estimate of time spent. The research and development costs include the following: payroll, consulting and contract labor, lab supplies and pharmaceutical preparations, legal, insurance, rent and utilities, and depreciation.
Income Taxes	Income Taxes
	The Company accounts for income taxes under the liability method in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 “Income Taxes”. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established if it is more likely than not that all, or some portion, of deferred income tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset would increase income in the period such determination was made.
	The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained upon an examination. Any recognized income tax positions would be measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement would be reflected in the period in which the change in judgment occurs. The Company would recognize any corresponding interest and penalties associated with its income tax positions in income tax expense. There were no income taxes, interest or penalties incurred in 2014, 2013 or 2012. Tax years going back to 2011 remain open for examination by the IRS.
Basic and Diluted Loss Per Common Share	Basic and Diluted Loss Per Common Share
Basic and Diluted Loss Per Common Share	Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options and warrants and convertible preferred stock as they are antidilutive. Potential common shares excluded from the calculation for the years ended December 31, 2014, 2013 and 2012, respectively, are 63,235,956, 73,037,416 and 30,038,017 from warrants, 10,845,098, 15,322,206 and 15,140,956 from options, and 0, 33,334 and 2,478,185 from convertible preferred shares.
Derivative Instruments	Derivative Instruments

	The warrants issued in conjunction with convertible preferred stock in March and April 2010 private placements include a reset provision if the Company issues additional warrants, in certain circumstances as defined in the agreement, below the exercise price of $1.00. Effective January 1, 2009, the reset provision of these warrants preclude equity accounting treatment under ASC 815. Accordingly, the Company is required to record the warrants as liabilities at their fair value upon issuance and remeasure the fair value at each period end with the change in fair value recorded in the statement of operations. When the warrants are exercised or cancelled, they are reclassified to equity. The Company uses the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used at December 31, 2014 include a weighted average term of 0.2 years, a 5% probability that the warrant exercise price would be reset, a volatility of 63.7% and a risk free interest rate that ranges between 0.03% and 0.04%. Significant assumptions used at December 31, 2013 include a weighted average term of 1.2 years, a 5% probability that the warrant exercise price would be reset, a volatility range between 64.7% and 69.5% and a risk free interest rate range between 0.13% and 0.38%.

	Additionally, the Series A and Series C Warrants issued in conjunction with the January 2011 registered direct public offering include a reset provision if the Company issues additional warrants, in certain circumstances as defined in the agreement, below the exercise price of $1.12. During 2012, the warrant exercise price was reset to $0.675. Significant assumptions used at December 31, 2014 include a weighted average term of 1.0 years, a 5% probability that the warrant exercise price would be further reset, a volatility of 159.2% and a risk free interest rate range of 0.25%. Significant assumptions used at December 31, 2013 include a weighted average term of 2.0 years, a 5% probability that the warrant exercise price would be further reset, a volatility of 64.7% and a risk free interest rate that ranges between 0.38% and 0.78%.

	On February 22, 2013, the Company entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of an aggregate of $2,550,000 of Units at a purchase price of $0.75 per Unit. Each Unit consists of one share of Series A 8% Convertible Preferred Stock, par value $.001 per share, and a warrant to purchase one and one-quarter shares of the Company’s common stock, par value $.001 per share (subject to adjustment) at an exercise price of $1.00 per whole share (subject to adjustment). The total Series A 8% Convertible Preferred Stock issued was 3,400,001 shares, and the total warrants were 4,250,000. The Company used the net proceeds of the private placement for working capital, FDA trials, securing licensing partnerships, and general corporate purposes.



	The Company determined that warrants issued in February 2013 with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. At June 30, 2014, there are no remaining 2013 warrants and therefore no associated warrant liability. Significant assumptions used at December 31, 2013 include a weighted average term of 4.1 years, a 5% probability that the warrant exercise price would be reset, volatility of 67.2% and a risk free interest rate range between 0.78% and 1.78%.
Fair Value of Financial Instruments	Fair Value of Financial Instruments

	The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, short-term settlement receivable, other current assets and accounts payable approximate their fair value because of the short-term nature of these items. Cash equivalents are measured on a recurring basis within the fair value hierarchy using Level 1 inputs.

	The fair value of derivative instruments is determined by management with the assistance of an independent third party valuation specialist. Certain derivatives with limited market activity are valued using externally developed models that consider unobservable market parameters.
Stock-Based Compensation	Stock-Based Compensation

	The compensation cost relating to share-based payment transactions is measured based on the fair value of the equity or liability instruments at date of issuance and is expensed on a straight-line basis. The Company utilizes the Black-Scholes option-pricing model for purposes of estimating the fair value of each stock option on the date of grant. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock (as determined by reviewing its historical public market closing prices).

	Warrants to non-employees are generally vested and nonforfeitable upon the date of the grant. Accordingly fair value is determined on the grant date.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.
	The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2017. The Company currently does not have revenues but will consider any related impact going forward.
	In June 2014, the FASB issued Accounting Standards Update 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (ASU 2014-10), which eliminates the concept of a development stage entity (DSE) from U.S. GAAP. This change rescinds certain financial reporting requirements that have historically applied to DSEs and is intended to result in cost-savings for affected entities, such as certain start-up or research and development entities. The new standard also changes one related aspect of the variable interest entity (VIE) consolidation guidance in Topic 810.

	ASU 2014-10 is effective for public entities for annual reporting periods beginning after December 15, 2014 and interim periods therein. Early adoption is permitted. We early adopted ASU 2014-10 in our consolidated financial statements as of the third quarter of fiscal 2014.
	In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (ASU 2014-15), which addresses when and how to disclose going-concern uncertainties in the financial statements. ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year after the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The amended guidance is not expected to have a material impact on the Company’s consolidated financial statements.

Stock_Incentive_Plan_and_Warra1

Stock Incentive Plan and Warrants (Tables)	12 Months Ended
Stock Incentive Plan and Warrants (Tables)	Dec. 31, 2014
Fair Value of Option Granted to Employees	For stock options granted to employees during 2014, 2013 and 2012, the Company has estimated the fair value of each option granted using the Black-Scholes option pricing model with the following assumptions:



		2014		2013	2012
	Weighted average fair value per options granted	$0.77		$0.57	$0.73
	Significant assumptions (weighted average) risk-free interest rate at grant date	0.25%		0.25%	0.25%
	Expected stock price volatility	85% – 92%		83% – 85%	83% – 87%
	Expected option life (years)	10		10	10
Summary of Options Granted, Exercised, Outstanding and Exercisable	The following table summarizes the options granted, exercised, outstanding and exercisable as of December 31, 2012, 2013 and 2014:



		Shares			Exercise Price		Weighted
					Per Share		Average
							Exercise
							Price
	Outstanding at January 1, 2012		14,890,956		$	0.32 – 1.50	$	0.98
	Granted		250,000		$	0.84 – 0.93	$	0.86
	Exercised		—			—		—
	Forfeited		—			—		—

	Outstanding and exercisable at December 31, 2012		15,140,956		$	0.32 – 1.50	$	0.97

	Outstanding at January 1, 2013		15,140,956		$	0.32 – 1.50	$	0.97
	Granted		250,000		$	0.67	$	0.67
	Exercised		(43,750	)	$	0.32 – 0.60	$	0.48
	Forfeited		(25,000	)	$	0.6	$	0.6

	Outstanding and exercisable at December 31, 2013		15,322,206		$	0.62 – 1.50	$	0.97

	Outstanding at January 1, 2014		15,322,206		$	0.62 – 1.50	$	0.97
	Granted		150,000		$	0.88	$	0.88
	Settlement		(2,800,000	)	$	0.93 – 1.00	$	0.97
	Exercised		(1,502,108	)	$	0.64 – 1.25	$	0.96
	Forfeited		(325,000	)	$	0.95 – 1.10	$	1.09

	Outstanding and exercisable at December 31, 2014		10,845,098		$	0.64 – 1.50	$	0.97

Summary of Stock Options Outstanding	The following table summarizes information about stock options outstanding at December 31, 2014 in order of issuance from oldest to newest.



	Exercise Price	Number			Weighted		Outstanding		Number		Exercisable
		Outstanding			Average		Weighted		Exercisable		Weighted
		at December 31,			Remaining		Average		at December 31,		Average
		2014			contractual		Exercise price		2014		Exercise
					Life						Price
	$0.64		376,764			0.00 years	$	0.64		376,764	$	0.64
	$0.75		708,334			0.42 years	$	0.75		708,334	$	0.75
	$0.94		575,000			0.92 years	$	0.94		575,000	$	0.94
	$1.02		4,135,000			1.50 years	$	1.02		4,135,000	$	1.02
	$1.50		200,000			2.50 years	$	1.5		200,000	$	1.5
	$1.16		50,000			3.42 years	$	1.16		50,000	$	1.16
	$1.00		150,000			3.50 years	$	1		150,000	$	1
	$1.04		250,000			4.50 years	$	1.04		250,000	$	1.04
	$1.16		250,000			5.50 years	$	1.16		250,000	$	1.16
	$1.00		1,600,000			5.50 years	$	1		1,600,000	$	1
	$1.04		250,000			6.50 years	$	1.04		250,000	$	1.04
	$0.99		50,000			6.50 years	$	0.99		50,000	$	0.99
	$0.93		1,600,000			6.67 years	$	0.93		1,600,000	$	0.93
	$0.93		50,000			7.38 years	$	0.93		50,000	$	0.93
	$0.84		200,000			7.50 years	$	0.84		200,000	$	0.84
	$0.67		250,000			8.71 years	$	0.67		250,000	$	0.67
	$0.88		150,000			9.67 years	$	0.88		150,000	$	0.88

			10,845,098			3.85 years	$	0.97		10,845,098	$	0.97

Summary of Nonvested Stock Option Activity	The following is a summary of nonvested stock option activity for the year ended December 31, 2014:



		Number of Shares			Weighted Average
		Number of Shares			Grant-Date Fair Value
	Nonvested at December 31, 2013		—		$	—
	Granted		150,000		$	0.77
	Vested		(150,000	)	$	0.77
	Canceled		—			—

	Nonvested at December 31, 2014		—		$	—

Summary of the Aggregate Intrinsic Value of Shares Outstanding and Exercisable	The following is a summary of the aggregate intrinsic value of shares outstanding and exercisable at December 31, 2014. The aggregate intrinsic value of stock options outstanding and exercisable is defined as the difference between the market value of the Company’s stock as of the end of the period and the exercise price of the stock options which are in the money.


		Number of Shares			Aggregate Intrinsic
		Number of Shares			Value
	Outstanding and Exercisable at December 31, 2014		10,845,098		$	128,199

Warrants [Member]
Summary of Warrants Granted, Exercised, Outstanding and Exercisable	The following table summarizes the warrants granted, exercised, outstanding and exercisable as of December 31, 2012, 2013 and 2014.



		Warrants			Exercise Price		Weighted Average
		Warrants			Per Warrant		Exercise Price
	Outstanding at January 1, 2012		25,119,247		$	0.91 – 2.00	$	1.15
	Granted		10,399,414		$	0.68 – 1.50	$	1
	Exercised		—			—		—
	Forfeited		(5,480,644	)	$	0.91 – 1.50	$	1.29

	Outstanding and exercisable at December 31, 2012		30,038,017		$	0.68 – 2.00	$	1.05

	Outstanding at January 1, 2013		30,038,017		$	0.68 – 2.00	$	1.05
	Granted		53,675,050		$	0.68 – 1.12	$	1
	Exercised		(8,379,845	)	$	0.68 – 1.25	$	0.93
	Forfeited		(2,295,806	)	$	0.68 – 1.12	$	0.87

	Outstanding and exercisable at December 31, 2013		73,037,416		$	0.68 – 2.00	$	1.03

	Outstanding at January 1, 2014		73,037,416		$	0.68 – 2.00	$	1.03
	Granted		9,415,673		$	1.00 – 3.00	$	1.61
	Exercised		(17,524,498	)	$	0.68 – 1.50	$	1.01
	Forfeited		(1,692,635	)	$	0.95 – 1.25	$	1.07

	Outstanding and exercisable at December 31, 2014		63,235,956		$	0.68 – 3.00	$	1.12

Summary of Warrants Outstanding	The following table summarizes information about warrants outstanding at December 31, 2014.


	Exercise Price	Number Outstanding			Weighted Average		Weighted Average
		and Exercisable at			Remaining		Exercise Price
		December 31, 2014			Contractual Life in
					Years
	$0.68		134,994			1	$	0.68
	$0.95		187,467			0	$	0.95
	$1.00		48,844,755			3.3	$	1
	$1.12		1,793,036			1.42	$	1.12
	$1.25		8,782,703			2.98	$	1.25
	$1.50		670,001			1.3	$	1.5
	$1.75		200,000			1	$	1.75
	$2.00		323,000			2.25	$	2
	$2.50		300,000			4.33	$	2.5
	$3.00		2,000,000			4.33	$	3

			63,235,956			3.19	$	1.12

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Reconciliations between Statutory Federal Income Tax Rate and Company's Effective Tax Rate	Reconciliations between the statutory federal income tax rate and the Company’s effective tax rate follow:


		2014						2013						2012
	Years Ended December 31,	Amount			%			Amount			%			Amount			%
	Federal statutory rate	$	(3,483,000	)		(34.0	)	$	(9,417,000	)		(34.0	)	$	(4,273,000	)		(34.0	)
	State taxes		(461,000	)		(4.5	)		(1,246,000	)		(4.5	)		(566,000	)		(4.5	)
	Adjustment to valuation allowance		4,862,000			47.7			5,015,000			18.1			4,596,000			36.5
	Non-deductible compensation		—			—			—			—			924,000			7
	(Gain) loss on warrant liability		(918,000	)		(9.2	)		5,648,000			20.4			(681,000	)		(5.0	)

	Actual tax benefit	$	—			—		$	—			—		$	—			—

Components of Company's Deferred Income Taxes	The components of the Company’s deferred income taxes are summarized below:



	December 31,	2014			2013
	Deferred tax assets
	Net operating loss carry-forwards	$	34,046,000		$	30,995,000
	Stock-based compensation		6,344,000			6,299,000
	Warrants for services		5,421,000			4,527,000

	Deferred tax asset		45,811,000			41,821,000
	Deferred tax liabilities
	Patent amortization		(1,380,000	)		(1,638,000	)
	Valuation allowance		(44,431,000	)		(40,183,000	)

	Net deferred taxes	$	—		$	—

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Estimated Fair Value of Warrants

The Company used the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used are as follows:

December 31, 2014

December 31, 2013

December 31, 2012

2010 Warrants:

Weighted average term

0.2 years

1.2 years

2.2 years

Probability the warrant exercise price would be reset

Volatility

63.70%

66.5% to 69.5%

58.9% to 63.4%

Risk free interest rate

0.03% to 0.04%

0.13% to 0.38%

0.25% to 0.36%

2011 Warrants:

Weighted average term

1.0 years

2.0 years

3.0 years

Probability the warrant exercise price would be reset

Volatility

159.20%

64.70%

58.9% to 63.4%

Risk free interest rate

0.25%

0.38% to 0.78%

0.25% to 0.36%

2013 Warrants:

Weighted average term

N/A

4.1 years

N/A

Probability the warrant exercise price would be reset

N/A

Volatility

N/A

67.20%

N/A

Risk free interest rate

N/A

0.78% to 1.78%

N/A

Warrant Liability Measured at Fair Value on a Recurring Basis

The warrant liability measured at fair value on a recurring basis is as follows:

Total

Level 1

Level 2

Level 3

Derivative instruments:

Warrant liability at December 31, 2014

146,560

—

146,560

Warrant liability at December 31, 2013

12,866,572

—

12,866,572

Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis

Balance at January 1, 2013

1,299,570

Issuance of warrants

1,297,950

Net loss included in earnings

14,671,130

Exercise of warrants

(4,402,078

)

Balance at December 31, 2013

12,866,572

Balance at January 1, 2014

12,866,572

Issuance of warrants

—

Net gain included in earnings

(2,384,393

)

Exercise of warrants

(10,335,619

)

Balance at December 31, 2014

146,560

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
Selected Quarterly Financial Data (Unaudited) (Tables)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Results of Operations	The following tables present a summary of quarterly results of operations for 2014 and 2013:


		Three Months Ended
		March 31,			June 30,			September 30,			December 31,
		2014			2014			2014			2014
		(in thousands, except per share data)
	Consolidated Statement of Operations Data:
	Gain on settlement – net of discount	$	—		$	—		$	—		$	4,178
	Total operating loss not including gain on settlement		(4,382	)		(4,160	)		(3,826	)		(4,443	)
	Other income (expense), net		(2,285	)		3,517			77			1,081

	Net income (loss)		(6,667	)		(643	)		(3,749	)		816

	Net income (loss) applicable to common stockholders	$	(6,667	)	$	(643	)	$	(3,749	)	$	816

	Basic and diluted income (loss) per common share	$	(0.04	)	$	(0.00	)	$	(0.02	)	$	0
	Weighted average number of common shares outstanding – basic and diluted		168,860			175,554			179,089			182,057


		Three Months Ended
		March 31,			June 30,			September 30,			December 31,
		2013			2013			2013			2013
		(in thousands, except per share data)
	Consolidated Statement of Operations Data:
	Total operating loss	$	(3,247	)	$	(3,287	)	$	(3,650	)	$	(2,844	)
	Other income (expense), net		(923	)		909			(903	)		(13,754	)

	Net loss		(4,170	)		(2,378	)		(4,553	)		(16,598	)
	Dividends on preferred stock		(1,077	)		(72	)		(38	)		—

	Net loss applicable to common stockholders	$	(5,247	)	$	(2,450	)	$	(4,591	)	$	(16,598	)

	Basic and diluted loss per common share	$	(0.04	)	$	(0.02	)	$	(0.03	)	$	(0.11	)
	Weighted average number of common shares outstanding – basic and diluted		120,702			127,115			131,574			148,314

Organization_and_Significant_A2

Organization and Significant Accounting Policies - Additional Information (Detail) (USD $)	0 Months Ended		12 Months Ended			1 Months Ended
	Mar. 31, 2013	Feb. 22, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 28, 2013	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013	Jun. 30, 2013	Jun. 30, 2012
Property, Plant and Equipment [Line Items]
Material revenue			$0
Maturity of highly liquid investments			Three months or less
Amount of insurance coverage				250,000
Impairment			0
Reduced amount of deferred tax asset			0
Recognized income tax positions measured			50.00%
Income taxes, interest or penalties incurred			0	0	0
Exercise price of common stock	$1		$1.25	$1	$1		$1.25	$3	$1	$1	$1.25
Weighted average term			2 months 12 days	1 year 2 months 12 days
Probability that the warrant exercise price would be reset			5.00%	5.00%
Minimum range of risk free interest rate			0.03%	0.13%
Maximum range of risk free interest rate			0.04%	0.38%
Minimum volatility range that the warrant exercise price				64.70%
Maximum volatility range that the warrant exercise price would be reset				69.50%
Volatility rate that the warrant exercise price			63.70%
Risk free interest rate			0.25%	0.25%	0.25%
Issuance and sale in a private placement accredited to investors		2,550,000
Convertible preferred stock	8.00%
Purchase price of common stock	$0.75	$0.75								$0.75
8% convertible preferred stock, par value		$0.00
Preferred stock, par value		$0.00	$0.00	$0.00
Common stock, par value		$0.00	$0.00	$0.00
Minimum [Member]
Property, Plant and Equipment [Line Items]
Volatility rate that the warrant exercise price			85.00%	83.00%	83.00%
Maximum [Member]
Property, Plant and Equipment [Line Items]
Volatility rate that the warrant exercise price			92.00%	85.00%	87.00%
Patents [Member]
Property, Plant and Equipment [Line Items]
Expected annual amortization of patents			2 years
Amortization of patents, 2015			671,000
Amortization of patents, 2016			671,000
Amortization of patents, 2017			659,000
Amortization of patents, 2018			659,000
Amortization of patents, 2019			547,000
Patents [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Remaining lives of the patents			2 years
Patents [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Remaining lives of the patents			7 years
8% Convertible Preferred Stock [Member]
Property, Plant and Equipment [Line Items]
Exercise price of common stock			$1
Common Stock [Member]
Property, Plant and Equipment [Line Items]
Exercise price of common stock		$1
Warrants [Member]
Property, Plant and Equipment [Line Items]
Exercise price of common stock			$1.12
Weighted average term			1 year	2 years
Probability that the warrant exercise price would be reset			5.00%	5.00%
Minimum range of risk free interest rate				0.38%
Maximum range of risk free interest rate				0.78%
Volatility rate that the warrant exercise price			159.20%	64.70%
Risk free interest rate			0.25%		0.68%
Warrants [Member]
Property, Plant and Equipment [Line Items]
Antidilutive common shares excluded from the calculation of loss per share			63,235,956	73,037,416	30,038,017
Equity Option [Member]
Property, Plant and Equipment [Line Items]
Antidilutive common shares excluded from the calculation of loss per share			10,845,098	15,322,206	15,140,956
8% Convertible Preferred Stock [Member]
Property, Plant and Equipment [Line Items]
Antidilutive common shares excluded from the calculation of loss per share			0	33,334	2,478,185
Series A 8% Convertible Preferred Stock [Member]
Property, Plant and Equipment [Line Items]
Weighted average term				4 years 1 month 6 days
Probability that the warrant exercise price would be reset				5.00%
Minimum range of risk free interest rate				0.78%
Maximum range of risk free interest rate				1.78%
Maximum volatility range that the warrant exercise price would be reset				67.20%
Convertible preferred stock		8.00%		8.00%		8.00%
Preferred stock, shares issued		3,400,001	0	33,334
Warrants issued		4,250,000
Remaining 2013 warrants								0
Associated warrant liability								$0
Computer Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets			5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets			7 years

Commitments_Additional_Informa

Commitments - Additional Information (Detail) (USD $)	12 Months Ended
Commitments - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]
Rent Expense	$60,000	$55,379	$55,378
Lease renewable period	1 year
Employment agreement period for executive	5 years
Automatic employment renewal period for executive	1 year
Initial base salary	$500,000

Equity_Transactions_Additional

Equity Transactions - Additional Information 1 (Detail) (USD $)	3 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012
Class of Stock [Line Items]
Issuance of common stock to consultants	75,000	75,000	75,000	75,000	275,000	75,000	75,000	75,000	75,000	225,000	75,000	175,000
Common Stock [Member]
Class of Stock [Line Items]
Consulting costs charges	72,000	68,500	140,250	137,500	214,000	51,250	49,500	48,750	47,250	184,750	64,500	160,000

Equity_Transactions_Additional1

Equity Transactions - Additional Information 2 (Detail) (USD $)	0 Months Ended	3 Months Ended												12 Months Ended				1 Months Ended		0 Months Ended	1 Months Ended
	Mar. 31, 2013	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 30, 2010	Mar. 31, 2010	Jul. 22, 2013	Dec. 31, 2010
Class of Stock [Line Items]
Issuance of warrants to consultants		1,503,913	6,000	202,000	733,000	209,473	442,000	2,605,000	1,924,973	452,500	1,732,135	454,500	1,003,000
Consulting costs charges related to warrants		$966,819	$4,189	$450,002	$900,317	$259,306	$186,223	$931,655	$409,640	$130,697	$721,753	$183,908	$475,668
Warrants expired										987,667	122,833	4,368,644	1,500
Warrants forfeited		1,027,635	228,500	315,000	121,500	247,973	136,500	1,051,500	859,833
Warrants exercised on cashless basis				1,594,082	12,522,198	4,480,005
Shares issued in cashless exercise				915,467	9,100,824	2,386,004
Warrants exercised				372,000	3,036,218	3,899,840
Common stock to be issued on exercise of warrant				372,000	3,036,218	3,899,840									372,000	3,899,840
Exercise price of warrants				372,000	2,672,364	3,412,392
Exercise price of common stock	$1	$1.25	$1.25	$3		$1	$1	$1	$1	$1		$1.25		$1.25	$3	$1	$1
Reduced exercise price due to new issuance price										$0.68							$0.68
Gain loss on revaluation of warrants liability														959,320		3,873,187	495,338
Gross proceeds from private offering of common stock and warrants to accredited investors		4,198,300				5,820,588	4,613,037	2,641,501	4,045,510	2,379,365		2,077,796			5,000,000
Company accepted subscriptions in aggregate		4,198,300	3,586,300			7,760,784	6,150,718	3,522,001	5,394,013	3,172,486		1,855,176			2,000,000
Period of warrants to purchase common stock							5 years			5 years
Investors received five year warrants		50.00%	50.00%			150.00%	150.00%	150.00%				100.00%			100.00%
Purchase price of common stock with warrants		$1	$1			$0.75	$0.75			$0.75		$1.12			$2.50
Percentage of Aggregate Shares Called by Warrant						10.00%				10.00%
Expiration of warrants						5 years
Aggregate amount of common stock			3,586,300
Convertible preferred stock	8.00%
Warrants exercised				133,232	1,756,665	1,146,662
Adjusted fair value of warrants exercised, reclassified into additional paid in capital						765,997								2,377,133
Loss from the revaluation of the warrant liability																-6,911,583
Warrants [Member]
Class of Stock [Line Items]
Exercise price of common stock		$1.12												$1.12
Gain on change in fair value of warrant liability														4,222,519			1,272,580
Warrants exercised				200,000	1,650,000
Loss from the revaluation of the warrant liability														-878,806		-3,886,360
8% Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock																		8.00%	8.00%
Five Year Warrant [Member]
Class of Stock [Line Items]
Exercise price of common stock			$1.25
Gross proceeds from private offering of common stock and warrants to accredited investors			15,000,000
Period of warrants to purchase common stock							5 years	5 years	5 years			5 years
Common Stock to be Issued on Exercise of Warrant	7,277,264	2,099,150	1,793,150	2,000,000		11,641,176	9,226,077	5,283,003	7,277,264			1,855,176		2,099,150	2,000,000	11,641,176
Purchase price of common stock with warrants			$1
Expiration of warrants		5 years	5 years			5 years									5 years
Series A Warrant [Member]
Class of Stock [Line Items]
Exercise price of common stock										$1.12							$1.12
Series C Warrants [Member]
Class of Stock [Line Items]
Exercise price of common stock										$1.12							$1.12
Alpha Capital Anstalt [Member]
Class of Stock [Line Items]
Purchase agreement date of agreement																				22-Jul-13
Purchase of common stock																				30,000,000
Term of purchase Agreement																				30 months
Purchase of common stock																				100,000
Issue of common stock																				250,000
Costs charged to operations for commitment fee																				162,500
Number of consecutive business day																				12 days
Network 1 Financial Securities [Member]
Class of Stock [Line Items]
Common stock to be issued on exercise of warrant	539,401	419,830	358,630	300,000		776,078	615,072	352,200	539,401	317,249		371,035		419,830	300,000	776,078	317,249
Exercise price of common stock	$1	$1.25	$1.25	$2.50		$1	$1	$1	$1	$1		$1.12		$1.25	$2.50	$1	$1
Common Stock to be Issued on Exercise of Warrant										3,172,486							3,172,486
Payment of fully vested warrants		545,779	466,219			747,302	564,686	314,173	522,640	279,317					650,000
Percentage of Aggregate Shares Called by Warrant		10.00%	10.00%			10.00%	10.00%	10.00%	10.00%	10.00%		20.00%			15.00%
Maxim Group LLC [Member]
Class of Stock [Line Items]
Common stock to be issued on exercise of warrant						175,000	358,333			94,667						175,000	94,667
Exercise price of common stock						$1	$1			$1						$1	$1
Gross proceeds from private offering of common stock and warrants to accredited investors						1,312,500	2,687,500			710,000
Company accepted subscriptions in aggregate						1,750,000	3,583,333			946,666
Common Stock to be Issued on Exercise of Warrant						2,625,000	5,375,000			946,666						2,625,000	946,666
Purchase price of common stock with warrants							$0.75
Payment of fully vested warrants						170,625	349,375			97,300
Percentage of Aggregate Shares Called by Warrant							10.00%
Lincoln Park Capital Fund LLC [Member]
Class of Stock [Line Items]
Additional purchase of common stock																					30,000,000
Purchase price of common stock																					$0.75
Term of purchase																					30 months
Maximum [Member]
Class of Stock [Line Items]
Fair market value for the warrants issued										$0.47				$2.56		$1.97
Investors received five year warrants						150.00%			150.00%	100.00%
Maximum [Member] \| Alpha Capital Anstalt [Member]
Class of Stock [Line Items]
Regular purchase limit																				$250,000
Maximum [Member] \| Maxim Group LLC [Member]
Class of Stock [Line Items]
Investors received five year warrants							150.00%
Minimum [Member]
Class of Stock [Line Items]
Fair market value for the warrants issued										$0.24				$0.55		$0.10
Investors received five year warrants									100.00%
Minimum [Member] \| Alpha Capital Anstalt [Member]
Class of Stock [Line Items]
Purchase agreement, per share value of common stock																				$0.75

Equity_Transactions_Additional2

Equity Transactions - Additional Information 3 (Detail) (USD $)	3 Months Ended										12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Jun. 30, 2012	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 22, 2013
Class of Stock [Line Items]
Series A warrants exercised			133,232	1,756,665	1,146,662
Adjusted fair value of warrants exercised, reclassified into additional paid in capital					$765,997						$2,377,133
Gain loss on revaluation of warrants liability											959,320		3,873,187	495,338
Gross proceeds from private offering of common stock and warrants to accredited investors	4,198,300				5,820,588	4,613,037	2,641,501	4,045,510	2,379,365	2,077,796		5,000,000
Company accepted subscriptions in aggregate	4,198,300	3,586,300			7,760,784	6,150,718	3,522,001	5,394,013	3,172,486	1,855,176		2,000,000
Period of warrants to purchase common stock						5 years			5 years
Investors received five year warrants	50.00%	50.00%			150.00%	150.00%	150.00%			100.00%		100.00%
Exercise price of common stock	$1.25	$1.25	$3		$1	$1	$1	$1	$1	$1.25	$1.25	$3	$1	$1
Purchase price of common stock with warrants	$1	$1			$0.75	$0.75			$0.75	$1.12		$2.50
Common stock to be issued on exercise of warrant			372,000	3,036,218	3,899,840							372,000	3,899,840
Percentage of Aggregate Shares Called by Warrant					10.00%				10.00%
Purchase price of common stock							$0.75	$0.75							$0.75
Maximum [Member]
Class of Stock [Line Items]
Investors received five year warrants					150.00%			150.00%	100.00%
Minimum [Member]
Class of Stock [Line Items]
Investors received five year warrants								100.00%
Network 1 Financial Securities [Member]
Class of Stock [Line Items]
Common Stock to be Issued on Exercise of Warrant									3,172,486					3,172,486
Exercise price of common stock	$1.25	$1.25	$2.50		$1	$1	$1	$1	$1	$1.12	$1.25	$2.50	$1	$1
Common stock to be issued on exercise of warrant	419,830	358,630	300,000		776,078	615,072	352,200	539,401	317,249	371,035	419,830	300,000	776,078	317,249
Percentage of Aggregate Shares Called by Warrant	10.00%	10.00%			10.00%	10.00%	10.00%	10.00%	10.00%	20.00%		15.00%
Payment of fully vested warrants	545,779	466,219			747,302	564,686	314,173	522,640	279,317			650,000
Warrant accrued							32,500
Maxim Group LLC [Member]
Class of Stock [Line Items]
Gross proceeds from private offering of common stock and warrants to accredited investors					1,312,500	2,687,500			710,000
Company accepted subscriptions in aggregate					1,750,000	3,583,333			946,666
Common Stock to be Issued on Exercise of Warrant					2,625,000	5,375,000			946,666				2,625,000	946,666
Exercise price of common stock					$1	$1			$1				$1	$1
Purchase price of common stock with warrants						$0.75
Common stock to be issued on exercise of warrant					175,000	358,333			94,667				175,000	94,667
Percentage of Aggregate Shares Called by Warrant						10.00%
Payment of fully vested warrants					170,625	349,375			97,300
Maxim Group LLC [Member] \| Maximum [Member]
Class of Stock [Line Items]
Investors received five year warrants						150.00%
Five Year Warrant [Member]
Class of Stock [Line Items]
Gross proceeds from private offering of common stock and warrants to accredited investors		15,000,000
Period of warrants to purchase common stock						5 years	5 years	5 years		5 years
Common Stock to be Issued on Exercise of Warrant	2,099,150	1,793,150	2,000,000		11,641,176	9,226,077	5,283,003	7,277,264		1,855,176	2,099,150	2,000,000	11,641,176
Exercise price of common stock		$1.25
Purchase price of common stock with warrants		$1
Series A Warrants [Member]
Class of Stock [Line Items]
Series A warrants exercised				858,825	1,269,520
Series C Warrants [Member]
Class of Stock [Line Items]
Series C warrants exercised				697,092	748,663
Exercise price of common stock									$1.12					$1.12
Series A and Series C Warrants [Member]
Class of Stock [Line Items]
Adjusted fair value of warrants exercised, reclassified into additional paid in capital				$3,911,370	$1,620,081

Equity_Transactions_Additional3

Equity Transactions - Additional Information 4 (Detail) (USD $)	0 Months Ended							3 Months Ended			12 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2013	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012
Class of Stock [Line Items]
Common stock shares issued in lieu of cash dividend														12,066	34,598	29,384	61,022	69,222	61,424	58,490	64,183
Dividends on preferred stock	$28,104	$50,860	$29,063	$37,478	$43,884	$51,194	$50,631	$38,000	$72,000	$1,077,000	$0	$1,188,648	$183,187
Dividends on preferred stock	10,586		21,921									29,063
8% Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Dividends on preferred stock		$22,164

Equity_Transactions_Additional4

Equity Transactions - Additional Information 5 (Detail) (USD $)	0 Months Ended								1 Months Ended	3 Months Ended						12 Months Ended			1 Months Ended	3 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Feb. 22, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Jan. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 28, 2013	Dec. 31, 2012	Sep. 30, 2012	Mar. 31, 2012	Sep. 30, 2014	Oct. 31, 2013	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012
Class of Stock [Line Items]
Converted preferred stock									33,334			2,925,000	441,667
Preferred stock converted into shares	441,667								33,334			2,925,000	441,667				2,925,000
Convertible preferred stock			8.00%
Issuance and sale in a private placement accredited to investors				$2,550,000
Purchase price of common stock		$0.75	$0.75	$0.75										$0.75	$0.75
8% convertible preferred stock, par value				$0.00
Preferred stock, par value				$0.00								$0.00				$0.00	$0.00
Common stock, par value				$0.00								$0.00				$0.00	$0.00
Exercise price of common stock	$1	$1	$1		$1		$1.25			$3		$1	$1	$1	$1	$1.25	$1	$1		1			$1.25
Common stock unit fair value warrants recorded on issuance																			1,297,950
Common stock unit beneficial conversion amount																			1,025,950
Issued warrants												2,400,000
Adjusted fair value of warrants exercised												765,997				2,377,133
Loss from the revaluation of the warrant liability																	-6,911,583
Warrants exercised										133,232	1,756,665	1,146,662
Dividends on preferred stock	28,104	50,860	29,063		37,478	43,884	51,194	50,631					38,000	72,000	1,077,000	0	1,188,648	183,187
Common stock shares issued in lieu of cash dividends for preferred stock																								12,066	34,598	29,384	61,022	69,222	61,424	58,490	64,183
Common Stock [Member]
Class of Stock [Line Items]
Exercise price of common stock				$1
Warrants [Member]
Class of Stock [Line Items]
Exercise price of common stock																$1.12
Loss from the revaluation of the warrant liability																-878,806	-3,886,360
Warrants exercised										200,000	1,650,000
Series A 8% Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock				8.00%													8.00%		8.00%
Preferred stock, shares issued				3,400,001								33,334				0	33,334
Warrants issued				4,250,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Adjusted fair value of warrants exercised												$2,016,000				$4,047,116
Common stock shares issued in lieu of cash dividends for preferred stock																								32,033	79,401
Redeemable Preferred Stock [Member]
Class of Stock [Line Items]
Converted preferred stock												746,666	734,999	403,520	593,000					463,480	490,000	100,000
Preferred stock converted into shares	734,999	403,520	593,000		463,480	490,000		100,000				746,666	734,999	403,520	593,000		746,666	463,480		463,480	490,000	100,000

Stock_Incentive_Plan_and_Warra2

Stock Incentive Plan and Warrants - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

Jul. 29, 2014

Feb. 26, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

27-May-14

Jun. 30, 2014

Dec. 31, 2014

Mar. 31, 2014

14-May-12

Aug. 19, 2013

Jun. 28, 2012

Jun. 30, 2013

29-May-13

Employees

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of long - term incentive compensation plans

Two

Number of Shares forfeited

300,000

Number of stock option issued

150,000

Stock-based compensation expense

$115,645

$142,310

$183,028

Total intrinsic value of options exercised

1,327,300

7,000

Unrecognized stock-based compensation expense

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Period of plan

10 years

Employee One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

25,000

Number of employees

Exercise price/share

$0.95

Common stock value

23,750

Number of Shares forfeited

25,000

Non Employee Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of employees

Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of employees

Options Exercised Price One [Member] | Employee One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

96,875

25,000

Number of employees

Exercise price/share

0.64

$0.95

Common stock value

62,000

23,750

Options Exercised Price One [Member] | Employee Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

300,000

Exercise price/share

$1.10

Common stock value

330,000

Options Exercised Price One [Member] | Employee Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

100,000

189,624

Exercise price/share

$1.25

$1.10

Common stock value

125,000

208,586

Options Exercised Price One [Member] | Non Employee [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

25,000

Exercise price/share

$0.95

Common stock value

23,750

Options Exercised Price Two [Member] | Employee One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

126,361

14,248

Exercise price/share

0.64

$0.75

Common stock value

80,871

10,686

Options Exercised Price Three [Member] | Employee One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

600,000

Exercise price/share

$0.93

Common stock value

558,000

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

18,450,000

Stock Options [Member] | Newly Appointed Board Member [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

50,000

Stock Options [Member] | Re Elected Board Member [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

250,000

200,000

Stock Options [Member] | Employee One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

18,750

Number of employees

Exercise price/share

$0.32

Common stock value

6,000

Stock Options [Member] | Other Employee [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

25,000

Number of employees

Exercise price/share

$0.60

Common stock value

$15,000

Number of Shares forfeited

25,000

Stock Compensation Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

20,000,000

2014 Equity Compensation Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

20,000,000

Stock_Incentive_Plan_and_Warra3

Stock Incentive Plan and Warrants - Fair Value of Option Granted to Employees (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value per options granted	$0.77	$0.57	$0.73
Significant assumptions (weighted average) risk-free interest rate at grant date	0.25%	0.25%	0.25%
Expected stock price volatility	63.70%
Expected option life (years)	10 years	10 years	10 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	85.00%	83.00%	83.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	92.00%	85.00%	87.00%

Stock_Incentive_Plan_and_Warra4

Stock Incentive Plan and Warrants - Summary of Options Granted, Exercised, Outstanding and Exercisable (Detail) (USD $)	0 Months Ended			12 Months Ended
	Oct. 03, 2014	Jul. 29, 2014	Feb. 26, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted		150,000		150,000
Number of Shares, Settlement	-2,800,000
Number of Shares, Forfeited			-300,000
Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Outstanding, Beginning balance				15,322,206	15,140,956	14,890,956
Number of Shares Outstanding, Ending balance					15,322,206	15,140,956
Exercise price, minimum				0.62	$0.32	$0.32
Exercise price, maximum				1.5	$1.50	$1.50
Weighted Average Exercise Price Outstanding, Beginning balance				0.97	$0.97	$0.98
Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted				150,000	250,000	250,000
Exercise price, minimum						$0.84
Exercise price, maximum				0.88	$0.67	$0.93
Weighted Average Exercise Price, Granted				0.88	$0.67	$0.86
Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price, minimum				0.64	$0.32
Exercise price, maximum				1.25	$0.60
Number of Shares, Exercised				-1,502,108	-43,750
Weighted Average Exercise Price, Exercised				0.96	$0.48
Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price, minimum				0.95
Exercise price, maximum				1.1	$0.60
Number of Shares, Forfeited				-325,000	-25,000
Weighted Average Exercise Price, Forfeited				1.09	$0.60
Range Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Outstanding, Beginning balance				15,322,206	15,140,956
Number of Shares Outstanding, Ending balance				10,845,098	15,322,206	15,140,956
Exercise price, minimum				0.64	$0.62	$0.32
Exercise price, maximum				1.5	$1.50	$1.50
Weighted Average Exercise Price Outstanding, Ending balance				0.97	$0.97	$0.97
Range Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price, minimum				0.93
Number of Shares, Settlement				-2,800,000
Exercise price, maximum				1
Weighted Average Exercise Price, Settlement				0.97

Stock_Incentive_Plan_and_Warra5

Stock Incentive Plan and Warrants - Summary of Stock Options Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	10,845,098
Weighted Average Remaining contractual Life	3 years 10 months 6 days
Outstanding Weighted Average Exercise price	$0.97
Number Exercisable at December 31, 2014	10,845,098
Exercisable Weighted Average Exercise Price	$0.97
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	376,764
Weighted Average Remaining contractual Life	0 years
Outstanding Weighted Average Exercise price	$0.64
Number Exercisable at December 31, 2014	376,764
Exercisable Weighted Average Exercise Price	$0.64
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	708,334
Weighted Average Remaining contractual Life	5 months 1 day
Outstanding Weighted Average Exercise price	$0.75
Number Exercisable at December 31, 2014	708,334
Exercisable Weighted Average Exercise Price	$0.75
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	575,000
Weighted Average Remaining contractual Life	11 months 1 day
Outstanding Weighted Average Exercise price	$0.94
Number Exercisable at December 31, 2014	575,000
Exercisable Weighted Average Exercise Price	$0.94
Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	4,135,000
Weighted Average Remaining contractual Life	1 year 6 months
Outstanding Weighted Average Exercise price	$1.02
Number Exercisable at December 31, 2014	4,135,000
Exercisable Weighted Average Exercise Price	$1.02
Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	200,000
Weighted Average Remaining contractual Life	2 years 6 months
Outstanding Weighted Average Exercise price	$1.50
Number Exercisable at December 31, 2014	200,000
Exercisable Weighted Average Exercise Price	$1.50
Range Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	50,000
Weighted Average Remaining contractual Life	3 years 5 months 1 day
Outstanding Weighted Average Exercise price	$1.16
Number Exercisable at December 31, 2014	50,000
Exercisable Weighted Average Exercise Price	$1.16
Range Seven [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	150,000
Weighted Average Remaining contractual Life	3 years 6 months
Outstanding Weighted Average Exercise price	$1
Number Exercisable at December 31, 2014	150,000
Exercisable Weighted Average Exercise Price	$1
Range Eight [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	250,000
Weighted Average Remaining contractual Life	4 years 6 months
Outstanding Weighted Average Exercise price	$1.04
Number Exercisable at December 31, 2014	250,000
Exercisable Weighted Average Exercise Price	$1.04
Range Nine [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	250,000
Weighted Average Remaining contractual Life	5 years 6 months
Outstanding Weighted Average Exercise price	$1.16
Number Exercisable at December 31, 2014	250,000
Exercisable Weighted Average Exercise Price	$1.16
Range Ten [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	1,600,000
Weighted Average Remaining contractual Life	5 years 6 months
Outstanding Weighted Average Exercise price	$1
Number Exercisable at December 31, 2014	1,600,000
Exercisable Weighted Average Exercise Price	$1
Range Eleven [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	250,000
Weighted Average Remaining contractual Life	6 years 6 months
Outstanding Weighted Average Exercise price	$1.04
Number Exercisable at December 31, 2014	250,000
Exercisable Weighted Average Exercise Price	$1.04
Range Twelve [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	50,000
Weighted Average Remaining contractual Life	6 years 6 months
Outstanding Weighted Average Exercise price	$0.99
Number Exercisable at December 31, 2014	50,000
Exercisable Weighted Average Exercise Price	$0.99
Range Thirteen [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	1,600,000
Weighted Average Remaining contractual Life	6 years 8 months 1 day
Outstanding Weighted Average Exercise price	$0.93
Number Exercisable at December 31, 2014	1,600,000
Exercisable Weighted Average Exercise Price	$0.93
Range Fourteen [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	50,000
Weighted Average Remaining contractual Life	7 years 4 months 17 days
Outstanding Weighted Average Exercise price	$0.93
Number Exercisable at December 31, 2014	50,000
Exercisable Weighted Average Exercise Price	$0.93
Range Fifteen [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	200,000
Weighted Average Remaining contractual Life	7 years 6 months
Outstanding Weighted Average Exercise price	$0.84
Number Exercisable at December 31, 2014	200,000
Exercisable Weighted Average Exercise Price	$0.84
Range Sixteen [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	250,000
Weighted Average Remaining contractual Life	8 years 8 months 16 days
Outstanding Weighted Average Exercise price	$0.67
Number Exercisable at December 31, 2014	250,000
Exercisable Weighted Average Exercise Price	$0.67
Range Seventeen [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding at December 31, 2014	150,000
Weighted Average Remaining contractual Life	9 years 8 months 1 day
Outstanding Weighted Average Exercise price	$0.88
Number Exercisable at December 31, 2014	150,000
Exercisable Weighted Average Exercise Price	$0.88

Stock_Incentive_Plan_and_Warra6

Stock Incentive Plan and Warrants - Summary of Nonvested Stock Option Activity (Detail) (USD $)	0 Months Ended	12 Months Ended
	Jul. 29, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Nonvested, Beginning balance, Number of Shares		0
Granted, Number of Shares	150,000	150,000
Vested, Number of Shares		-150,000
Canceled, Number of Shares		0
Nonvested, Ending balance, Number of Shares		0	0
Nonvested, Outstanding, Beginning balance, Weighted Average Grant-Date Fair Value		$0
Granted, Weighted Average Grant-Date Fair Value		$0.77	$0.57	$0.73
Vested, Weighted Average Grant-Date Fair Value		$0.77
Canceled, Weighted Average Grant-Date Fair Value		$0
Nonvested, Outstanding, Ending balance, Weighted Average Grant-Date Fair Value		$0	$0

Stock_Incentive_Plan_and_Warra7

Stock Incentive Plan and Warrants - Summary of the Aggregate Intrinsic Value of Shares Outstanding and Exercisable (Detail) (USD $)	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares	10,845,098
Aggregate Intrinsic Value	$128,199

Stock_Incentive_Plan_and_Warra8

Stock Incentive Plan and Warrants - Summary of Warrants Granted, Exercised, Outstanding and Exercisable (Detail) (USD $)	0 Months Ended		12 Months Ended
	Jul. 29, 2014	Feb. 26, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants, Granted	150,000		150,000
Number of Warrants, Forfeited		-300,000
Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Outstanding, Beginning balance			15,322,206	15,140,956	14,890,956
Number of Shares Outstanding, Ending balance				15,322,206	15,140,956
Exercise Price Per Warrant, Minimum			0.62	$0.32	$0.32
Exercise Price Per Warrant, Maximum			1.5	$1.50	$1.50
Weighted Average Exercise Price Outstanding and exercisable, Ending balance				$0.97	$0.97
Weighted Average Exercise Price Outstanding, Beginning balance			0.97	$0.97	$0.98
Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants, Granted			150,000	250,000	250,000
Exercise Price Per Warrant, Minimum					$0.84
Exercise Price Per Warrant, Maximum			0.88	$0.67	$0.93
Weighted Average Exercise Price, Granted			0.88	$0.67	$0.86
Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Warrant, Minimum			0.64	$0.32
Number of Warrants, Exercised			-1,502,108	-43,750
Exercise Price Per Warrant, Maximum			1.25	$0.60
Weighted Average Exercise Price, Exercised			0.96	$0.48
Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Warrant, Minimum			0.95
Exercise Price Per Warrant, Maximum			1.1	$0.60
Number of Warrants, Forfeited			-325,000	-25,000
Weighted Average Exercise Price, Forfeited			1.09	$0.60
Range Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Outstanding, Beginning balance			15,322,206	15,140,956
Number of Shares Outstanding, Ending balance			10,845,098	15,322,206	15,140,956
Exercise Price Per Warrant, Minimum			0.64	$0.62	$0.32
Exercise Price Per Warrant, Maximum			1.5	$1.50	$1.50
Warrants [Member] \| Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Outstanding, Beginning balance			73,037,416	30,038,017	25,119,247
Number of Shares Outstanding, Ending balance				73,037,416	30,038,017
Exercise Price Per Warrant, Minimum			0.68	$0.68	$0.91
Exercise Price Per Warrant, Maximum			2	$2	$2
Weighted Average Exercise Price Outstanding and exercisable, Ending balance				$1.03	$1.05
Weighted Average Exercise Price Outstanding, Beginning balance			1.03	$1.05	$1.15
Warrants [Member] \| Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants, Granted			9,415,673	53,675,050	10,399,414
Exercise Price Per Warrant, Minimum			1	$0.68	$0.68
Exercise Price Per Warrant, Maximum			3	$1.12	$1.50
Weighted Average Exercise Price, Granted			1.61	$1	$1
Warrants [Member] \| Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Warrant, Minimum			0.68	$0.68
Number of Warrants, Exercised			-17,524,498	-8,379,845
Exercise Price Per Warrant, Maximum			1.5	$1.25
Weighted Average Exercise Price, Exercised			1.01	$0.93
Warrants [Member] \| Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Warrant, Minimum			0.95	$0.68	$0.91
Exercise Price Per Warrant, Maximum			1.25	$1.12	$1.50
Number of Warrants, Forfeited			-1,692,635	-2,295,806	-5,480,644
Weighted Average Exercise Price, Forfeited			1.07	$0.87	$1.29
Warrants [Member] \| Range Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Outstanding, Beginning balance			73,037,416	30,038,017
Number of Shares Outstanding, Ending balance			63,235,956	73,037,416	30,038,017
Exercise Price Per Warrant, Minimum			0.68	$0.68	$0.68
Exercise Price Per Warrant, Maximum			3	$2	$2
Weighted Average Exercise Price Outstanding and exercisable, Ending balance			1.12	$1.03	$1.05
Weighted Average Exercise Price Outstanding, Beginning balance			1.03	$1.05

Stock_Incentive_Plan_and_Warra9

Stock Incentive Plan and Warrants - Summary of Warrants Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding and Exercisable at December 31, 2013	63,235,956
Weighted Average Remaining Contractual Life in Years	3 years 2 months 9 days
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding and Exercisable at December 31, 2013	134,994
Weighted Average Remaining Contractual Life in Years	1 year
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding and Exercisable at December 31, 2013	187,467
Weighted Average Remaining Contractual Life in Years	0 years
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding and Exercisable at December 31, 2013	48,844,755
Weighted Average Remaining Contractual Life in Years	3 years 3 months 18 days
Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding and Exercisable at December 31, 2013	1,793,036
Weighted Average Remaining Contractual Life in Years	1 year 5 months 1 day
Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding and Exercisable at December 31, 2013	8,782,703
Weighted Average Remaining Contractual Life in Years	2 years 11 months 23 days
Range Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding and Exercisable at December 31, 2013	670,001
Weighted Average Remaining Contractual Life in Years	1 year 3 months 18 days
Range Seven [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding and Exercisable at December 31, 2013	200,000
Weighted Average Remaining Contractual Life in Years	1 year
Range Eight [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding and Exercisable at December 31, 2013	323,000
Weighted Average Remaining Contractual Life in Years	2 years 3 months
Range Nine [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding and Exercisable at December 31, 2013	300,000
Weighted Average Remaining Contractual Life in Years	4 years 3 months 29 days
Range Ten [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding and Exercisable at December 31, 2013	2,000,000
Weighted Average Remaining Contractual Life in Years	4 years 3 months 29 days
Warrants [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted Average Exercise Price	1.12
Warrants [Member] \| Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted Average Exercise Price	0.68
Warrants [Member] \| Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted Average Exercise Price	0.95
Warrants [Member] \| Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted Average Exercise Price	1
Warrants [Member] \| Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted Average Exercise Price	1.12
Warrants [Member] \| Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted Average Exercise Price	1.25
Warrants [Member] \| Range Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted Average Exercise Price	1.5
Warrants [Member] \| Range Seven [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted Average Exercise Price	1.75
Warrants [Member] \| Range Eight [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted Average Exercise Price	2
Warrants [Member] \| Range Nine [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted Average Exercise Price	2.5
Warrants [Member] \| Range Ten [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted Average Exercise Price	3

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2014	Dec. 31, 2014
	NonEmployee	NonEmployee	Mar. 31, 2014	Directors
Related Party Transaction [Line Items]
Number of members to whom consulting services paid	1	1
Payment for consulting services	$54,000	$54,000
Non Employee [Member]
Related Party Transaction [Line Items]
Payment for consulting services to another non-employee	75,000	75,000
Shares issued in exchange for services		100,000
Consulting costs charges		47,520
Third Non Employee [Member]
Related Party Transaction [Line Items]
Payment for consulting services to another non-employee	75,000	75,000
Director [Member]
Related Party Transaction [Line Items]
Number of members to whom consulting services paid				1
Payment for consulting services			$6,000	$85,000

Income_Taxes_Reconciliations_b

Income Taxes - Reconciliations between Statutory Federal Income Tax Rate and Company's Effective Tax Rate (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Federal statutory rate, Value	($3,483,000)	($9,417,000)	($4,273,000)
State taxes, Value	-461,000	-1,246,000	-566,000
Adjustment to valuation allowance, Value	4,862,000	5,015,000	4,596,000
Non-deductible compensation, Value			924,000
(Gain) loss on warrant liability	-918,000	5,648,000	-681,000
Actual tax benefit, Value	$0	$0	$0
Federal statutory rate	-34.00%	-34.00%	-34.00%
State taxes	-4.50%	-4.50%	-4.50%
Adjustment to valuation allowance	47.70%	18.10%	36.50%
Non-deductible compensation			7.00%
(Gain) loss on warrant liability	-9.20%	20.40%	-5.00%
Actual tax benefit	0.00%	0.00%	0.00%

Income_Taxes_Components_of_Com

Income Taxes - Components of Company's Deferred Income Taxes (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets
Net operating loss carry-forwards	$34,046,000	$30,995,000
Stock-based compensation	6,344,000	6,299,000
Warrants for services	5,421,000	4,527,000
Deferred tax asset	45,811,000	41,821,000
Deferred tax liabilities
Patent amortization	-1,380,000	-1,638,000
Valuation allowance	-44,431,000	-40,183,000
Net deferred taxes	$0	$0

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Tax net operating losses	$99,000,000
Limitation of net operating loss carry-forward	3,200,000
Limitation of net operating loss carry-forward, description	The Company completed a Section 382 study for the period from inception through the year ended December 31, 2014 and recorded a limitation of $3.2 million of their net operating loss carry-forward.
Uncertain tax positions	$0	$0
Earliest Tax Year [Member]
Income Taxes [Line Items]
Operating losses expiration period	2022
Latest Tax Year [Member]
Income Taxes [Line Items]
Operating losses expiration period	2034

401_K_Profit_Sharing_Plan_Addi

401 (K) Profit Sharing Plan - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]
Contributions to the 401(K) Profit Sharing Plan	$320,000	$226,000	$132,000

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Estimated Fair Value of Warrants (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
2010 Warrants [Member]
Class of Stock [Line Items]
Weighted average term	2 months 12 days	1 year 2 months 12 days	2 years 2 months 12 days
Probability the warrant exercise price would be reset	5.00%	5.00%	5.00%
Volatility	63.70%
2010 Warrants [Member] \| Minimum [Member]
Class of Stock [Line Items]
Volatility		66.50%	58.90%
Risk free interest rate	0.03%	0.13%	0.25%
2010 Warrants [Member] \| Maximum [Member]
Class of Stock [Line Items]
Volatility		69.50%	63.40%
Risk free interest rate	0.04%	0.38%	0.36%
2011 Warrants [Member]
Class of Stock [Line Items]
Weighted average term	1 year	2 years	3 years
Probability the warrant exercise price would be reset	5.00%	5.00%	5.00%
Volatility	159.20%	64.70%
Risk free interest rate	0.25%
2011 Warrants [Member] \| Minimum [Member]
Class of Stock [Line Items]
Volatility			58.90%
Risk free interest rate		0.38%	0.25%
2011 Warrants [Member] \| Maximum [Member]
Class of Stock [Line Items]
Volatility			63.40%
Risk free interest rate		0.78%	0.36%
2013 Warrants [Member]
Class of Stock [Line Items]
Weighted average term		4 years 1 month 6 days
Probability the warrant exercise price would be reset		5.00%
Volatility		67.20%
2013 Warrants [Member] \| Minimum [Member]
Class of Stock [Line Items]
Risk free interest rate		0.78%
2013 Warrants [Member] \| Maximum [Member]
Class of Stock [Line Items]
Risk free interest rate		1.78%

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Warrant Liability Measured at Fair Value on a Recurring Basis (Detail) (Recurring [Member], Warrants [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$146,560	$12,866,572
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$146,560	$12,866,572

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis (Detail) (Recurring [Member], Level 3 [Member], Warrants [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Recurring [Member] \| Level 3 [Member] \| Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	$12,866,572	$1,299,570
Issuance of warrants		1,297,950
Net (gain) loss included in earnings	-2,384,393	14,671,130
Exercise of warrants	-10,335,619	-4,402,078
Ending Balance	$146,560	$12,866,572

Litigation_Additional_Informat

Litigation - Additional Information (Detail) (USD $)	0 Months Ended			3 Months Ended	12 Months Ended
Litigation - Additional Information (Detail) (USD $)	Oct. 03, 2014	Jul. 24, 2014	Jun. 06, 2014	Dec. 31, 2014	Dec. 31, 2014	Apr. 30, 2013
Loss Contingencies [Line Items]
Reserve for litigation						$100,000
Damages sought to be receivable			2,240,000
Estimated bonus percentage			70.00%
Future payment ratio of contingent consideration			2
Repayment under contingency			1,120,000
Reimbursement cost percentage			25.00%
Attorney's fees and reimbursement of expenses		911,000
Stock options	2,800,000
Gain related to litigation settlement				4,178,000	4,178,345
Short-term Receivable				733,333	733,333
Long-term Receivable				3,378,345	3,378,345
Discount for implied interest				301,655	301,655
Litigation settlement payment description					The cash settlement amounts will be repaid to the Company over a period of five years with the first payment due in October 2015 and the final payment is expected to be received by October 3, 2019.
Executive Officer [Member]
Loss Contingencies [Line Items]
Repayment under contingency					66,667
Number of shares acquired under litigation			1,000,000
Stock option issued to employees			100,000
Share-based compensation forfeiture rate			50.00%
Other Defendants [Member]
Loss Contingencies [Line Items]
Damages sought to be receivable			$25,000

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Unaudited) - Summary of Quarterly Results of Operations (Detail) (USD $)	0 Months Ended							3 Months Ended								12 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statement of Operations Data:
Gain on settlement - net of discount								$4,178,000								$4,178,345
Total operating loss												-2,844,000	-3,650,000	-3,287,000	-3,247,000	-12,633,028	-13,027,939	-14,337,619
Total operating loss not including gain on settlement								-4,443,000	-3,826,000	-4,160,000	-4,382,000
Other income (expense), net								1,081,000	77,000	3,517,000	-2,285,000	-13,754,000	-903,000	909,000	-923,000
Net income (loss)								816,000	-3,749,000	-643,000	-6,667,000	-16,598,000	-4,553,000	-2,378,000	-4,170,000	-10,242,990	-27,697,744	-12,568,354
Dividends on preferred stock	-28,104	-50,860	-29,063	-37,478	-43,884	-51,194	-50,631						-38,000	-72,000	-1,077,000	0	-1,188,648	-183,187
Net income (loss) applicable to common stockholders								$816,000	($3,749,000)	($643,000)	($6,667,000)	($16,598,000)	($4,591,000)	($2,450,000)	($5,247,000)	($10,242,990)	($28,886,392)	($12,751,541)
Basic and diluted income (loss) per common share								$0	($0.02)	$0	($0.04)	($0.11)	($0.03)	($0.02)	($0.04)
Weighted average number of common shares outstanding - basic and diluted								182,057,000	179,089,000	175,554,000	168,860,000	148,314,000	131,574,000	127,115,000	120,702,000	175,828,004	132,000,796	112,986,636